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RESEARCH PORTFOLIO ABSTRACT 
Introduction: The objective of this thesis was to examine aspects of emotion regulation in 
Multiple Sclerosis (MS). A systematic review was carried out of studies investigating the 
prevalence of alexithymia in individuals with MS, and its relationship with anxiety and 
depression.  An empirical study was conducted to explore whether there were differences in 
emotion regulation abilities in individuals with different variants of MS, compared to healthy 
individuals.  
Methods: Twelve journal articles were identified via systematic search utilising predefined 
criteria. Seventy nine individuals with relapsing-remitting type of MS, and 38 individuals with 
chronic progressive type of MS were recruited to the empirical study. Participants filled in self-
report questionnaires measuring difficulties in emotion regulation, illness severity, illness 
representations and quality of life. Also, 55 healthy volunteers took part in the current study. 
Results: The estimate of prevalence of alexithymia in MS was approximately twice as high as 
in general population. Positive relationships between alexithymia and/or anxiety and 
depressive symptoms were found. Those with MS reported difficulties accepting emotional 
distress which, to some extent, were predicted by strong illness identity and negative emotional 
responses to having MS. These findings were independently of illness severity, and type of 
MS. Perceptions of negative consequences of MS were the only partial mediator of the 
relationship between illness severity and quality of life.   
Conclusions: Larger and more representative samples are needed to clarify the impact of 
alexithymia on the clinical presentations of patients with MS. Psychological interventions 
targeting non-acceptance of emotional distress and negative illness perceptions are warranted 
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Systematic Review Abstract 
 
 
Objective: Large body of evidence across health conditions shows that the presence of 
alexithymia can adversely impact on functional and treatment outcomes. The main purpose of 
this review was to investigate the prevalence of alexithymia in Multiple Sclerosis and its 
relationship with mood difficulties, specifically anxiety and depressive symptoms.  
 
 
Method: A literature search for studies assessing alexithymia in Multiple Sclerosis was 
conducted. The following major electronic databases were systematically searched until 10th 
March 2017: EMBASE (from 1947), MEDLINE (from 1946), PsychINFO (from 1806) and 
SCOPUS (from 1960), with secondary sources sought, including references in primary articles. 
Relevant first authors were contacted. Attempts were made to obtain any existing grey 
literature. 
 
Results: Twelve observational studies met inclusion criteria. Presence of alexithymia, as 
determined by cut-off scores, was measured using self-report instruments, i.e. the Toronto 
Alexithymia Scale (by 10 studies) and the Bermond- Vorst Alexithymia Questionnaire (by two 
studies). Given methodological and reporting limitations, the most adequate estimate of 
prevalence of alexithymia in Multiple Sclerosis was 23%, and ranging from 10% - 31.6%. The 
balance of evidence indicated positive relationships between alexithymia and/or anxiety and 
depressive symptoms. 
 
Conclusions: Levels of alexithymia are significantly higher in Multiple Sclerosis, compared 
to rates of approximately 10% in general population. Thus, it might prove beneficial to target 
alexithymic features in psychological treatment of Multiple Sclerosis. Yet, further studies with 
larger and more representative patient samples are required to clarify the impact of alexithymia 
on the clinical features of patients with MS.  





The importance and prevalence of mood disturbance in Multiple Sclerosis (MS) has previously 
been highlighted in research literature on MS (Feinstein & Feinstein, 2001; Mohr & Cox, 2001; 
Dahl, Stordal, Lydersen, & Midgard, 2009), with the prevalence of anxiety and depressive 
symptoms estimated to be approximately 34% and 35% respectively (Boeschoten et al., 2017), 
compared to the prevalence of anxiety and depressive disorders in MS estimated at 10% and 
21% respectively (Boeschoten et al.,, 2017). Other emotional difficulties in MS are reported, 
such as emotional lability, pathological laughing and crying, as well as alexithymia (Montreuil 
& Petropoulou 2003; Montel & Bungener, 2007). It is important, from a clinical point of view, 
to investigate whether alexithymia is common in individuals with MS, since the presence of 
alexithymia is shown to affect suitability and outcomes to different types of psychological 
treatments, as well as has prognostic implications for those affected (Lumley, Neely, & Burger, 
2007). 
 
Further, alexithymia has been conceptualised as a vulnerability factor for the appearance of 
psychiatric and psychosomatic symptoms (Franz et al., 2008), being strongly related to 
depression and anxiety in the general population (Honkalampi, Hintikka, Tanskanen, 
Lehtonen, & Viinamäki, 2000; Marchessi & Maggini, 2001). There is also some evidence of 
the relationship between the presence of alexithymia and poorer therapeutic outcomes (Lumley 
et al., 2007). Thus, further exploring the evidence for the relationship between alexithymia and 
depression or anxiety in studies on MS might shed some light on whether alexithymic traits 
should be considered in the treatment of mood disorders in MS.  





Definition of alexithymia 
The alexithymia construct was first coined by Sifneos (1973) to capture a cluster of traits which 
were key to the clinical presentation of patients with psychosomatic disorder who were found 
not to benefit from insight- oriented psychotherapy approaches. The original view of 
alexithymia, which is widely acknowledged in contemporary research and theory (Taylor, 
Bagby, & Parker, 1997), is of emotional blindness; entailing a cluster of cognitive traits such 
as, difficulties with identifying and describing own emotional states to others, as well as having 
a predominantly externally-oriented thinking and reduced imaginative capacity. Therefore, 
individuals having alexithymia struggle with recognising and communicating how they feel, 
display little insight into their internal emotional states, subsequent symptoms and physical 
manifestations of their feelings (Nemiah, Freyberger, & Sifneos, 1976). Much less recognised 
alternative view of alexithymia is that of a global emotional processing impairment which 
restricts recognition and expression of one’s feelings (Lane, Sechrest, Riedel, Shapiro, & 
Kaszniak, 2000). Nevertheless, both constructs approve of alexithymia being an inability, 
deficit or deficiency in emotional processing rather than an active defensive process or 
maladaptive emotion regulation strategy (such as e.g. emotion suppression, inhibition or denial 
etc.), which limits the experience or expression of emotion (Lumley et al., 2007). Other 
emotion-related construct that is commonly mistaken for alexithymia is emotion regulation. 
Emotion regulation is a broader concept than alexithymia that encompasses a wide array of 
processes, such as accessing and expressing emotions, monitoring and controlling one’s 
feelings and accepting one’s emotional states (Dahl, 2003). The current systematic review 
article is focused solely on the original definition of alexithymia, for which a very large body 
of literature has been produced, primarily in physical and psychiatric health, with less focus 




Measurement issues in alexithymia 
Assessment tools of alexithymia have been developed over the past four decades with 
questionable psychometric properties, thus, resulting in clinical and research practice call for 
the development of measures that are shown to be valid and reliable. Given that the critical 
review of assessment measures of alexithymia is beyond the scope of this review, the reader is 
referred to several such reviews, comprehensively covering assessment methods that are 
interview-based, collateral informant-based, and self-reports (see e.g. Linden, Wen, & 
Paulhaus, 1994; Taylor, Bagby, & Luminet, 2000; Taylor et al., 1997; Lumley et al., 2007). 
The current review focuses on two alexithymia self-report tools used in research with 
participants with MS, namely the 20-item Toronto Alexithymia Scale (TAS-20; Bagby, Taylor, 
& Parker, 1994), as well as the Bermond- Vorst Alexithymia Questionnaire (BVAQ; Bermond 
& Vorst, 1998). 
Overall, self-report measures are the most extensively used in the assessment of alexithymia 
(Lumley et al., 2007). The Toronto group developed the TAS-20 to measure three aspects of 
alexithymia on a 5-point Likert-type scale, namely difficulty recognising own emotions (e.g. 
“I have feelings that I can’t quite identify”), difficulty describing feelings (e.g. “People tell me 
to describe my feelings more”), and externally oriented thinking (e.g. “I prefer to analyse 
problems rather than just describe them”). TAS-20 has an empirically–derived cut-off score 
that classifies people into having alexithemia (61-100), being borderline alexithymic (52-60), 
or non-alexithymic (20-51) despite scores being continuous. This measure has been utilised 
widely in both nonclinical and clinical populations, and has been, to our knowledge, the most 
extensively employed measure in alexithymia research as a whole, as well as in MS research. 
There is a wealth of data to support its convergent and discriminant validity, as well as to 
predict clinical criteria and basic emotional processes involved in alexithymia (Bagby et al., 
1994; Parker, Taylor, & Bagby, 2003; Zech, Luminet, Rimé, & Wagner, 1999).Given the 
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extensive validation of TAS-20, its brevity, ease of employment, and the possibility of 
comparison across various studies when utilising a common tool, the TAS-20 has become the 
golden standard in alexithymia evaluation in the literature. Yet, this measure is not without 
limitations. The three cognitive aspects of alexithymia captured by the TAS-20 have different 
number of items, with some aspects loading more than others to the total score which is used 
for the diagnosis of alexithymia. It has also been argued by some (e.g. Vorst & Bermond, 2001) 
that other essential aspects of alexithymia, such as ‘limited fantasizing’, as well as ‘limited 
experiencing of emotional states’ that are not included in this measure, ultimately limit the 
operationalization of this tool, providing a limited assessment of alexithymia.  
 
More recently developed BVAQ captures same aspects of alexithymia as the TAS-20 
(identifying, verbalizing and analysing), with an additional assessment of ‘emotionalizing’ and 
‘fantasizing’ (Vorst & Bermond, 2001), thus, arguably being a more comprehensive measure 
of alexithymic traits. These five aspects of alexithymia are measured on a 5-point Likert-type 
scale.  ‘Emotionalizing’ refers to the degree of arousal caused by emotional events (e.g. “When 
something unexpected happens, I remain calm and unmoved”), ‘fantasizing’ is the propensity 
to engage in daydreaming and imaginative thinking (e.g. “I have few daydreams and 
fantasies”), ‘identifying’ is defined as one’s capability to recognise own emotional states (e.g. 
“When I am tense, it remains unclear from which of my feelings this comes”), ‘analyzing’ is 
defined as one’s eagerness to seek out reasons for own emotional responses (e.g. “I hardly ever 
consider my feelings”), and ‘verbalizing’ is one’s ability to label or communicate own feelings 
(e.g. “I find it difficult to express my feelings”). The scale consists of two parallel versions (A 
and B) of 20 items each, with version B shown to be more psychometrically sound (Zech et al., 
1999). There is substantially less studies supporting evidence of adequate validity and 
reliability of BVAQ, despite moderate correlations of the BVAQ with the TAS-20 (Morera, 
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Culhane, Watson, & Skewes, 2005). The empirically derived cut-off score for determining the 
presence and absence of alexithymia is over 52 and below 44 respectively (Gay et al., 2017).  
Importantly, to best of our knowledge, the psychometric properties have been evaluated only 
for the TAS-20 in a sample of individuals with MS (Fernandez-Jimenez et al., 2013). Factorial 
validity and reliability were adequate, supporting the three factor structure of the Spanish 
adaptation of this measure.  
 
Prevalence in general population and non-neurological conditions 
It is believed that the prevalence of alexithymia in the general population is approximately 
10%, with somewhat higher rates for men (9% - 17%) than for women (10%-15%; Mattilaa, 
Salminenc, Nummia, & Joukamaa, 2006). Alexithymia appears to be normally distributed in 
both genders and therefore regarded by some as a personality dimension (Franz et al. 2008). 
Although some evidence suggests that alexithymia tends to be more prevalent in advanced age, 
in men rather than women (Honkalampi et al., 2000; Mattilaa et al., 2008), and in those with 
low educational level and socioeconomic status (Franz et al., 2008), the sizes of these 
relationships tend to be variable.  
 
Aggravated rates of alexithymia are found in patients with psychosomatic disorders (40-60%; 
Taylor et al., 1997), autism spectrum disorder (40%-60%; Berthoz & Hill, 2005), depressive 
disorders (32 - 51%; Marchesi et al., 2000; Saarijarvi, Salminen, & Toikka, 2001),  anxiety 
disorders (13% - 58%; Da & Taylor, 1993; Marchesi, Brusamonti, & Maggini, 2000), eating 
disorders (24% - 77%; de Zwaan et al., 1995), addictive disorders (30% - 50%; Evren et al., 
2008), and obsessive-compulsive disorder (11% - 36%; Grabe et al., 2006). Thus, it appears 




Prevalence of alexithymia in neurological conditions 
Alexithymia appears to have been most widely investigated in traumatic brain injury (TBI), 
with 30%-60% of those with TBI also meeting criteria for the diagnosis of alexithymia 
(Ricciardi, Demartini, Fotopoulou, & Edwards, 2015). Individuals with epileptic seizures were 
also found to have aggregated levels of alexithymic traits, ranging from 29% to 76% (Ricciardi 
et al., 2015). Recent systematic review of 11 studies on the prevalence of alexithymia in 
Parkinson’s disease, reported its prevalence to be between 18% - 23.8% (Assogna et al., 2016). 
Similarly to non-neurological conditions, the prevalence of alexithymia appears to be markedly 
higher in those aetiologically distinct neurological conditions. Yet, there is a body of evidence 
that these conditions, similarly to MS, are associated with the presence of various emotional 
difficulties other than alexithymia (Beyenburg et al., 2005; Fann, Hart, & Schomer, 2009; 
Péron et al., 2012).  
Moreover, there is neuroimaging evidence (Moriguchi & Komaki, 2013) that alexithymia is 
associated with reduced neural responses to emotional stimuli, and with decrease activity 
during imagery, in the limbic and paralimbic areas (i.e., anterior/posterior cingulate cortex, 
amygdala, insula). In contrast, alexithymia is also known to be associated with enhanced neural 
activity in somatosensory and sensorimotor regions, including the insula. As most of these 
areas have been found to be adversely affected by early stages of MS (Audoin et al., 2010), it 
seems reasonable to assume that the prevalence of alexithymia will also be heightened in 
people with MS. 
 
Rationale for the review: 
A large body of evidence across health conditions shows that the presence of alexithymia may 
adversely impact on functional outcomes (Lumley et al., 2007), and predicts patients’ prognosis 
in psychiatric, behavioural as well as medical treatments. Following from that, alexithymia 
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predicts poorer treatment outcomes, not only for somatoform disorders (Bach & Bach, 1995) 
and mixed psychiatric disorders (McCallum, Piper, Ogrodniczuk, & Joyce, 2003), but also for 
anxiety and depression (Ogrodniczuk, Piper, & Joyce, 2004). Since it appears likely that 
alexithymia hinders adjustment to illness and/or recovery, it is possible that it will also impact 
on rehabilitation treatment which is commonly offered to those with MS (and with other 
neurological conditions). It is therefore important to investigate the prevalence of alexithymia 
in MS. 
 
Moreover, taking into account alexithymic traits of individuals with MS and understanding 
their relationship with depression and anxiety can aid neuropsychological assessment and 
possibly result in treatment plans becoming more effective. This might be particularly relevant 
for psychological interventions which focus on close rapport with a therapist, rely on high 
degree of insight and emotional awareness, such as cognitive-behavioural therapy (CBT), 
acceptance-commitment therapy (ACT), as well as psychodynamic psychotherapy. Hence, the 
purpose of this review is to explore further the evidence for alexithymia in MS and its 





The primary aim of this review was to investigate the prevalence of alexithymia in individuals 
in MS. It was hypothesised that the prevalence of alexithymia would be heightened in people 




The secondary aim was to investigate the relationship between alexithymia and mood 
difficulties, specifically anxiety and depressive symptoms, in MS.  
 
Search strategy: 
Searches were carried out within the domains of keywords, title and abstract. The following 
major electronic databases were systematically searched until 10th March 2017: EMBASE 
(from 1947), MEDLINE (from 1946), PsychINFO (from 1806) and SCOPUS (from 1960). The 
following key terms were utilised in a search string: (“multiple sclerosis” OR “MS” OR 
“neurological disease”) AND (“alexithymia” OR “alexithymic” OR “emotion regulation” OR 
“emotion* dysregulation” OR “emotion* functioning” OR “emotion* recognition” OR 
“emotion* perception” OR “emotion* identification” OR “emotion* awareness” OR 
“emotion* unawareness” OR “emotion* blindness ” and “ emotion* lability”). Also, the 
Cochrane Database of Abstracts of Reviews of Effects (DARE) was searched to ensure that a 
similar review had not been carried out recently, using the same key terms.  
 
Inclusion/exclusion criteria for the assessment of included studies: 
 
It has been suggested by the Centre for Reviews and Dissemination (CRD; 2009) that poorer 
quality studies tend to report more favourable outcomes than high quality studies. This, 
however, might be an artefact of publication bias, with poorer quality studies being less likely 
to publish at all if they do not report favourable outcomes- such that similar quality studies that 
indicate no effect are not published. Studies exploring prevalence of alexithymia and group 
differences in alexithymia, as compared to general population, are mainly observational: case-
control or cross-sectional in design. Moreover, strong inferences about causality of effects or 
associations found cannot be made considering that variable are not manipulated under 
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experimental conditions, and participants are not randomly selected. Thus, these studies are 
placed at the lower end of evidence quality hierarchy (CRD, 2009).Yet, it is important to 
consider whether strategies to improve confidence in the results and to attempt reducing a risk 
of bias (by e.g. blind assessments of outcome or careful matching etc.) have been employed by 
those studies.  
 
The literature search, as well as consultation of the CRD (2009), Cochrane Collaboration 
(2011) and the Agency for Healthcare Research and Quality guidelines (AHRQ; 2012) revealed 
no particular recommended tool for evaluating risks of bias in observational studies. The 
aforementioned resources recommend employment of a domain-based evaluation tool (The 
Cochrane Collaboration, 2011), and question using a scale or a checklist that utilises summary 
scores, as such scores imply that all biased items are of similar risk to study’s findings. The 
CRD recommend the AHRQ tool for the quality assessment of observational studies, and to 
tailor it to best meet the requirements of the systematic review in question. This systematic 
review adopted the aforementioned quality assessment tool (see Table 1 in appendix A), with 
review criteria following internationally recognised guidelines produced by both, the Centre 
for Reviews and Dissemination (CRD), The University of York (www.york.ac.uk/inst/crd/), as 
well as the Scottish Intercollegiate Guidelines Network (SIGN 50, 2015). The quality 
assessment tool covers the domains of: detection bias, selection bias and confounding, validity 







The PCOS format (Population, Comparators, Outcomes, Study Design; CRD, 2009) was 
employed. Each quality criterion was given a rating of ‘yes’, ‘partially’, ‘no’, or ‘unclear’, with 
a rationale for the decision noted (see Table 2 below). Quality criteria 1, 2, 5 and 6 were 
relevant to the first aim of the review, with all of the criteria being relevant to the second aim 
of the review. An overall quality category was applicable only to those included studies which 
helped to address the secondary aim of the current review. An overall quality category, instead 
of a single summary score, was utilised with four possible ratings of: 
 ‘excellent’, i.e. All but one of the criteria are well covered, with up to one partially 
addressed. Limitations of the study are thought to be very unlikely to have affected the 
findings or conclusions drawn. 
 ‘very good’, i.e. All but two of the criteria are well covered, with up to two partially 
addressed. Limitations of the study are thought to be unlikely to have affected the 
findings or conclusions. 
 ‘reasonable’, i.e. At least 70% of criteria are either partially addressed or well covered 
, with up to one criterion being unmet or unclear. Limitations of the study may have 
modestly affected the findings or conclusions. 
 ‘limited’, i.e. Many or most criteria were partially addressed with some criteria being 
unmet and unclear. Limitations of the study are thought likely or very likely to have 
affected the findings or conclusions.  
 
An independent rater reviewed the quality of 50% of included studies, selected randomly. Exact 
agreement was achieved on 68% (54/80) of methodological quality ratings, with a difference 
of one point (e.g. yes versus partially or partially versus no) on 25% (20/80) of items and of 
two points (e.g. partially versus unclear) on 7% (6/80) of items. All differences between raters 
were discussed and amended where appropriate. 
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Table 2.  
Study Characteristics and Main Findings 
Author(s) and 
country of origin 














RRMS = 30  
(70% females),  
Age M = 34.2      (SD 
= 6.2),  
YoE M = 14.7  
 (SD = 2.0), 
MS duration  
M = 9.1  
(SD = 6.7), 
EDSS M = 2  
(SD = 1.0) 
McDonald criteria 
for diagnosis EDDS 
≤ 4.5, age 20-40, IQ 










The prevalence of alexithymia was 10%.  
 
10% (n = 3) of MS group met threshold for moderate depression. 
There were no participants meeting threshold for severe depression. 
 
Alexithymia scores significantly correlated with depression scores (r 





RRMS = 38  
(87.3% females) 
Age M = 42.3  
(SD = 11.3),  
YoE M = 15.4 
(SD = 2.8) 
EDSS M = 1.66  
(SD = 1.6),  
MS duration  
M = 1.6 (SD = 8.7, 
range 1.38-39.3 
years),  
MSSS M = 2.35  
(SD = 2.4) 
McDonald criteria 
for diagnosis, no 
other neurological 
or psychiatric 







TAS-20  The prevalence of alexithymia was 31.6%.  
 





MS = 60  




Age M = 35.2  
(SD = 8.9, range 18-
25),  
YoE – no data, 
MS duration 
M = 5.4 
(SD = 4.5), 
EDSS M = 1.31  (SD 
= 1.07) 
McDonald criteria 
for diagnosis for 
RRMS or SPMS, no 











The prevalence of alexithymia was 23.3%.  
 
Patil et al., (2016) 
 
Argentina 
RRMS = 38  (86.8% 
females),  
Age M = 42.3 
(SD = 11.3),  
YoE M = 15.4  
(SD = 2.8), 
MS duration 
M = 10.60 
(SD = 8.7), 
EDSS M = 1.66  (SD 
= 1.6),  






























MS = 35  
(34.3% females; SP 
= 29 (83%), RR = 5 
(14%), PP = 1 (3%),  
Age M = 48.2       (SD 
= 10.2),  
YoE M = 10.8    (SD 
= 2.3),  
MS duration 
M = 9.2  
(SD = 8.4), 
EDSS Median = 6.0 
(range 0-7.5) 
McDonald criteria 
for diagnosis: no 











The prevalence of alexithymia was 25.8%.  
 
According to the cut-off scores 17.1% (n = 6) of MS group was 
classified as depressed, 28.6% (n = 10) as moderately depressed, and 
45.7% (n =16) as not depressed. Missing data on 8.6% (n = 3).  
 
Correlational analysis between alexithymia and depression scores 
was not performed/reported. 
 
 




RRMS = 58 
(56.9% females), 
Age M = 34.8 
(SD = 9.3, range 28-
80),  
YoE – no data, 
education levels 
reported instead, 
EDSS Median= 1.5 
(range 0-6.0),  
MS duration  
M = 9.1  




for diagnosis for 
RRMS, MMSE 










Alexithymia was found in 13.8% of individuals with MS.  
 
Significantly higher levels of depression (p <.007, d = 1.06) were 
found in alexithymic patients (n = 8), when compared with non-
alexithymic patients (n = 37).TAS-20 total score and TAS-20 DIF 
subscale was associated with BDI scores. TAS-20 DIF subscale was 
the strongest factor associated with depression.   
 
Among the alexithymic group, 6 out of 8 (75%) were depressed         
(BDI ≥ 13), compared to 7 out of 37 (20.6%) from non-alexithymic 
group      (p = .02). 
 
Significant correlation between alexithymia and depression                   
(rho = .37, p <.004) 




MS = 61 (68.8% 
female; RR = 46 (75 
%), SP = 6 (9.8%) 
PP = 9 (14.8%),  
 
Age M = 41.1  
(SD = 10.8),  
 
YoE – no data, 
education levels 
reported instead,  
 
MS duration  
M = 9.28  
(SD = 7.51),  
 
EDDS M= 2.9 (SD = 
2.19) 










The prevalence of alexithymia was 42.5%. 
 
Alexithymics were significantly more depressed (F = 4.11, p = 0.02) 
than borderline alexithymics (d = 0.72) and non-alexithymics (d = 
0.71) with MS.  
Alexithymics were significantly more state anxious (F = 4.62, p = 
0.01,) than borderline alexithymics (d = 0.70) and non-alexithymics 
(d = 0.89) with MS.  
Alexithymics were significantly more trait anxious (F = 6.13, p = 
0.003) than borderline alexithymics (d = 0.93) and non-alexithymics 
(d = 0.84) with MS.  
The prevalence of depression was 34.4%, and trait anxiety was 
44.3%, and state anxiety was 29.6% 
 
Positive correlations between anxiety, depression and alexithymia 
scores were found: the TAS-20 DIF subscale significantly correlated 
with BDI (r =.31, p = .05), 
STAI-S (r =.43, p = .01), and  
STAI-T (r =.43, p =.01).  
The TAS-20 DDF subscale significantly correlated with STAI-S (r 
=.28, p = .05), and STAI-T (r =.31, p =.05).  
 
Depression, state and trait anxiety predicted 20% of variance in 
alexithymia scores. 
Fernandez-




MS = 221(63.03% 
female; RR = 172 
(77.8%); SP =39 
(17.7%), PP = 10 
(4.5%),  
McDonald criteria 
for diagnosis, no 






TAS-20  High degree of alexithymia was present in 18.1% of the sample.  
 




Age M = 40.61    (SD 
= 9.65), 
 YoE – no data, 
education levels 
reported instead,  
MS duration 
M = 8.45 
(SD = 6.23),  





Gay et al., (2010) 
 
France 
MS = 115 (68.6% 
females),  
Age M = 47.2  (SD = 
10.9, range 20-80),  
YoE – no data, 
education levels 
reported instead,  
MS duration         M 
= 15.3             (SD = 
10.05), 
EDDS M = 4.75   









Alexithymia, and satisfaction with social support system are partial 
mediators of the relationship between trait anxiety and depression in 
MS. Those variable explain 56.7% of the variance of depression.  
 
20.5% of individuals with MS had moderate depressive symptoms, 
5.4% severe depressive symptoms, as measured by the DRS,   36.4% 
state anxiety, 43.8% trait anxiety, as measured by STAI. 
 
Depressive symptoms strongly associated with alexithymia,  
r = .50, p <.001 
 




MS = 66 (62% 
female, RRMS = 41, 
(80.6%)), 
Age M = 41. 4 (SD = 
10.86, range 20-77),  
YoE = no data,  
MS duration         M 
= 10.9             (SD = 
8.66), 










Alexithymia positive linked to trait anxiety (r = .40, p < .01) and 
depression (r = .27, p < .05).  
 
Moderate trait anxiety in 15 (24.2%) and high trait anxiety in 12 
(19.4%).  
 








MS = 60  
(58% females, RR = 
30 (50%), SP = 15 
(25%), PP = 15 
(25%) 
Age M = 46.5      (SD 
= 10.6, range 18-60),  
YoE M = 12.9     (SD 
= 3.3), 
MS duration         M 
= 14.4             (SD = 
9.4, range 2-18 
years),  




























The prevalence of alexithymia was 12%.  
 
No significant relationships between alexithymia, depression and 
anxiety were found; pearson's r = .21 (p= .12) between z-score of 
BVAQ and z-score of BDI; pearson's r = .22 (p= .09) between z-score 









MS = 189  
(64% female; RR = 
108 (57 %); SP = 54 
(29%), PP = 28 
(15%)),  
Age M = 44.2      (SD 
= 12.5),  
YoE – no data, 
MS duration         M 
= 15.0 (SD = 9.29, 











The prevalence of alexithymia was 53%. 
 
Self-reported levels of anxiety (M = 5.8, SD = 3.78) and depression 
(M = 8.0, SD = 4.19) were in the normal range. At individual level, 
16/189 (8.5%) had both anxiety and depression, 8/189 (4.2%) had 
anxiety, 37/189 (19.6%) had depression). 
No statistically significant differences between depressed and non-
depressed in terms of alexithymia, F (2,186) = 1.36, p = 26, nor 
between anxious and non-anxious and alexithymia, F(2,186) = 1.99, 




EDDS M= 4.7     (SD 
= 2.37) 
Alexithymia did not correlate with depression (r = .07, p = ns), but 




Selected studies were based exclusively on human adults (age range of 18–65 years) with a 
clinical diagnosis of MS, regardless of nationality, race or gender. Studies that included 
individuals with other degenerative conditions of the Central Nervous System (e.g. dementia) 
were excluded, unless data of participants with MS were reported separately.  
 
Comparators 
Studies with and without healthy control (HC) groups were included. Data of HC was not 
considered, as it was not essential to answer review’s aims.  
Outcomes  
Presence of alexithymia, as determined by adequate cut-off scores, was the outcome of interest. 
Thus, only studies that included at least one validated observer and/or self-report measure of 
alexithymia were included in the review of the primary aim. Moreover, to be included in the 
review of the secondary aim, studies also required a measure of anxiety and/or depression.  
 
Study Design  
Studies included were in English and presented original data. Studies were selected based on 
the basis of study design, including observational investigations with cross-sectional or 
longitudinal design. Relevant first authors were contacted for additional information/data when 
needed. Conference abstracts were excluded unless additional details could be found. To 
reduce the impact of potential publication bias, B.R. contacted the primary authors of relevant 
conference abstracts to include any suitable unpublished studies. Eleven authors were 
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approached, of whom six did not respond, three could not be contacted, and two did not have 
the data presented in a reviewable format (i.e. manuscript, thesis etc.). Further attempt was 
made to include ‘grey literature’ into the current review by using the reference lists of published 
studies, searching on Google Scholar and greylit.org  for published reports/ academic theses 
using same abovementioned key terms. No further studies were found which could had been 




Characteristics of included studies 
The search process initially identified 95 studies (after excluding 59 duplicates). Both, titles 
and abstract of these 95 studies were investigated for their suitability, accounting for the 
inclusion and exclusion criteria detailed below. This resulted in 12 studies being retained for 
the systematic review (Bodini, Mandarelli, Tomassini, Tarsitani, Pestalozza et al., 2008; 
Cecchetto, Aiello, D’Amico, Cutuli, Cargnelutti et al., 2014; Chahraoui, Pinoit, Viegas, Adnet, 
Bonin et al., 2008; Chahraoui,  Duchene, Rollot, Bonin, & Moreau, 2014; Dulau, Deloire, Diaz, 
Saubusse, Charre-Morin, et al. 2017; Fernandez-Jimenez, Perez-San-Gregorio, Taylor, Bagby, 
Ayearst et al., 2013; Gay, Bungener, Thomas, Vrignaud, Thomas, et al., 2017; Gay, Vrignaud, 
Garitte, & Meunier, 2010; Gleichgerrcht, Tomashitis, & Sinay, 2015; Kuloglu, Saglam, 
Korkmaz, Saglam, Gurok et al., 2012; Patil, Young, Sinay, & Gleichgerrcht, 2016; Prochnow, 
Donell, Schafer, Jorgens, Hartung, 2011). The pathway of the literature review process in 
illustrated in Figure 1 below. Main characteristics and key findings of interest to this review 
are reported in Table 2 in Appendix A. Six studies were case-control studies, comparing 
individuals with MS to healthy controls, further five were cross-sectional observational studies, 
and one study was longitudinal observational in design, with individuals with MS only. Ten of 
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these studies used the TAS-20 to measure alexithymia in MS, with further two studies 
employing the BVQS. Seven of these studies further investigated the relationship with 
alexithymia and depression in MS. Five of these studies further investigated the relationship 
between alexithymia and anxiety in MS. The number of participants with MS varied in the 
studies from 30 to 221. Altogether, 971 individuals with MS (635 females; 65.4%) took part in 
these studies, with three of the studies (Chahraoui, et al., 2014; Gay et al., 2010; Kuloglu et al., 
2012) not reporting the exact figures for different clinical types of MS (n = 240). Based on the 
data reported in the remaining nine studies (n = 731), 525 individuals had RRMS (72%), 143 
had SPMS (19%), and 63 had PPMS (9%). These figures are similar to the distribution of 
clinical types in MS population (Neild, 2006). The included studies dated from 2008 to 2017, 
were published in English and originated from Argentina (2), France (5), Germany (1), Italy 





























N of records identified through 
database searching 
N = 154 
 
N of additional records identified 
through other sources 
N = 0 
N of records after duplicates removed 
N= 95 
N of records screened 
N = 95 
N of records excluded based on reading 
abstracts 
N= 61 
N of full-text articles excluded on 
alexithymia in disease/condition other 
than MS  
N = 7 
N of records excluded based on 
inability to access sufficient 
information about conference 
abstracts of studies on alexithymia in 















































Figure 1. The pathway of the literature review process.
N of records excluded as published in 
French and Spanish with only 
abstracts accessible in English 

















Quality assessment of included studies 
 
Evaluation of the methodological strength of the aforementioned studies using the AHRQ 
quality assessment was conducted by applying the quality criteria outlined in Table 1 above to 
each of the studies, with quality ratings presented in Table 3 below. This assessment 
highlighted key areas which are likely to have introduced bias into the studies and impacted on 
the results obtained. Five out of twelve studies (Chahraoui et al., 2008; Fernandez-Jimenez et 
al., 2013; Gay et al., 2010, 2017; Kuloglu et al., 2012) met criteria for ‘reasonable’ quality, 
with remaining seven having ‘limited’ quality (Bodini et al., 2008; Cecchetto et al., 2014; 
Gleichgerrcht et al., 2014; Chahraoui et al., 2014; Dulau et al., 2017; Patil et al., 2016; 
Prochnow et al., 2011). Studies with ‘reasonable’ quality tended to be characterised by more 
























































Case-control studies  measuring alexithymia with TAS-20 
 




PARTIALLY PARTIALLY N/A NO UNCLEAR N/A LIMITED 
Gleichgerrcht 
et al. (2015) 
PARTIALLY 
 
PARTIALLY N/A N/A NO UNCLEAR N/A LIMITED 
Kuloglu et al. 
(2012) 
PARTIALLY PARTIALLY N/A N/A PARTIALLY UNCLEAR N/A REASONABLE 
Patil et al. 
(2016) 
PARTIALLY PARTIALLY N/A N/A NO UNCLEAR N/A LIMITED  
Prochnow et 
al. (2011) 
PARTIALLY PARTIALLY PARTIALLY N/A NO UNCLEAR N/A LIMITED  
Observational studies measuring alexithymia with TAS-20   
 
Bodini et al. 
(2008) 
PARTIALLY PARTIALLY PARTIALLY N/A NO UNCLEAR YES LIMITED 
Chahraoui et 
al. (2014) 
PARTIALLY PARTIALLY PARTIALLY PARTIALLY NO NO YES LIMITED 
Chahraoui et 
al. (2008) 
PARTIALLY PARTIALLY PARTIALLY PARTIALLY PARTIALLY UNCLEAR YES REASONABLE 
Fernandez-
Jimenez et al. 
(2013) 















Gay et al. 
(2010) 
PARTIALLY PARTIALLY PARTIALLY PARTIALLY PARTIALLY PARTIALLY PARTIALLY REASONABLE 
Observational studies measuring alexithymia with BVAQ 
 
Dulau et al. 
(2017) 
PARTIALLY  PARTIALLY PARTIALLY PARTIALLY NO UNCLEAR YES LIMITED 
Gay et al. 
(2017) 
PARTIALLY PARTIALLY PARTIALLY PARTIALLY PARTIALLY NO PARTIALLY REASONABLE 
 
Note. Criteria 1, 2, 5 and 6 only were relevant to the first aim of the current review, with all of the criteria being relevant to the second aim. 




Areas of strength 
Most studies provided sufficient detail regarding the MS cohort, with key baseline 
demographics and appropriate inclusion/exclusion criteria being well specified, with 
recruitment settings reported. This enabled an understanding of the composition of the samples 
across the studies. The measures used for the assessment of alexithymia, depression and anxiety 
in MS were generally well validated (often in MS population) and reliable, with adequate 
analytical techniques and reporting of statistical data.  
 
Areas of weakness 
Although most studies used adequate inclusion/exclusion criteria and described key 
demographic variables of the sample, the samples were likely to be of limited 
representativeness of MS population. Five out of 12 studies had homogenous samples, included 
people with RRMS only, with lower neurological disability (i.e. MS severity as measured by 
the EDDS) and shorter MS duration. Likewise, most of the remaining studies predominantly 
included people with RRMS which reflects the prevalence of different types of MS in the 
population, and clinical accessibility to those with this most prevalent type of MS. Yet, having 
the majority of studies conducted on people with the RRMS will unavoidable limit the 
generalisability of the findings to other types of MS, such as SPMS and PPMS. More 
importantly, there appeared to be a lack of a priori power calculations to establish sample sizes 
needed to achieve sufficient statistical power. The majority of the studies were underpowered 
which further limits the representativeness of their small samples and their ability to reliably 
obtain the results they reported. Only five out of 12 studies had sufficient power to detect large 
to moderate effect sizes, with no studies having large enough samples to detect small magnitude 
of the effects. In sum, the risk of sampling and detection bias was high in the included studies.  
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Aligned to the abovementioned limitations, is the issue of sampling procedures not being 
specified by most of the studies, with four reporting convenience sampling procedure 
(Chahraoui et al., 2014; Fernandez-Jimenez et al., 2013; Gay et al., 2010, 2017). It is very 
likely that members of the target population did not have equal chances of being selected, as 
no forms of randomisation were reported and most studies recruited their participants from 
clinical settings; outpatient and inpatient MS clinics and university hospitals (see Table 4 in 
appendix B for more details). Thus, there is a lack of population-based studies in this area of 
research, with only one study (by Gay et al., 2010) recruiting individuals with MS from various 
MS associations. However, individuals with MS who are recruited from clinical setting rather 
than the community might not be necessarily less representative of the population, since MS is 
a disease variable in its course and progression, with a vast majority of those in the community, 
regardless of the type of MS, requiring inpatient care at various points in their lives (Boeschten 
et al., 2017). Taken together, where recruitment and sampling procedures for individuals with 
MS are not clearly stated which was often the case for the majority of the studies, adequate 
representativeness of the samples and future replication of these studies is limited.  
 
Although, the measures used for the assessment of alexithymia (the TAS-20, the BVAQ), 
depression (the BDI, the DRS, the HADS) and anxiety (the HADS, the STAI) were all 
psychometrically sound measures (with English versions evaluated in many clinical 
populations), only one study reported psychometric properties for the language appropriate 
adaptations of these measures in MS population (Fernandez- Jimenez et al., 2013). However, 
most of the studies provided references for validation studies conducted on samples from 
language-appropriate general populations, for alexithymia measures; the TAS-20 and the 
BVAQ. Only the studies of Gay et al. (2010, 2017) referred the reader to the validation studies 
of the depression measures used; the DRS was validated on English-speaking general 
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population, the HADS was validated on MS English-speaking population, and separately on 
French-speaking general population (see Table 4 in appendix B for more details). Yet, none of 
those were reported to be validated on MS French-speaking population, as required for these 
studies. Similarly, only the studies of Chahraoui et al. (2008, 2014) and Gay et al. (2010, 2017) 
referred the reader to the validation studies of the anxiety measures used; the STAI was 
validated on the French-speaking general populations, and the HADS on MS English-speaking 
population, with none of those reported to be validated on MS French-speaking population, as 
again required for these studies. None of the studies using the BDI for the assessment of 
depression, reported or referred the reader to appropriate validation studies of this measure. 
Hence, we independently examined the psychometric properties for the BDI and found 
evidence of adequate validity and reliability for MS populations for English, French and Italian 
adaptations of the BDI (see Hind et al., 2016 for a review). It is likely that there is evidence for 
validity and reliability of all the language-specific adaptations of the measures used by the 
studies, for MS population, and simply they were not reported due to journal’s stringent word 
limits. Alternatively validation studies for use of these measures in other languages could had 
been published in those languages rather than English. Hence, we were unable to access and 
verify such studies.   
 
Related to the aforementioned issue is the application of adequate cut-off scores. All studies 
reported the cut-off scores utilised to assess the presence of alexithymia. However, this was 
rarely the case for the studies that also investigated anxiety and depression in MS, making it 
impossible to reliably estimate the presence of depression and anxiety in those studies. Ten out 
of 12 studies used the TAS-20 to investigate the prevalence of alexithymia in MS, yet with 
somewhat different cut-off scores. As detailed in table 5 in appendix C, the cut-off scores for 
the presence of alexithymia were largely the same (equal or larger than 61, out of 100) across 
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different empirically derived scoring criteria, such as the Toronto team cut-off values, the 
internationally accepted cut-off values, and the North American cut-off values. The French cut-
off values were more inclusive, with a cut-off score equal to or larger than 53 out of 100. Only 
one (Chahraoui et al., 2008) out of five French studies (Chahraoui et al., 2008) used the French 
cut-off. Yet, the original thresholds proposed by the Toronto team (Bagby et al., 1994) are also 
validated for the use with the French adaptation of TAS-20 (Loas et al., 1996), and the use of 
these thresholds would largely facilitate comparisons with other studies. There were more 
significant differences for cut-off scores differentiating those with borderline alexithymia and 
those with absence of alexithymia across those different scoring criteria applied by the included 
studies. Hence, it was impossible to reliably estimate the percentage of people with borderline 
alexithymia in MS. It is unclear whether the remaining two studies (Dulau et al., 2017; Gay et 
al., 2017) which employed the BVAQ to assess alexithymia, used same cut-off scores. Gay et 
al. (2017) applied the cut-off score of 52 and over as indicative of the presence of alexithymia, 
whereas Dulau et al. (2017) employed a cut-off score that was less than the 5th percentile of 
the matched HC score (-1.64 SD), without specifying the actual value of the score. 
 
Finally, it is unclear whether the majority of included studies used blinding procedures, 
suggesting they were not used. Only the study by Gay et al. (2010) reported that participants 
were blinded to the actual research questions, with no studies reporting an application of a 
double-blinded procedure. It would be difficult for the researchers not to realise which 
participants were the ones with MS, considering the prominent gait difficulties of many people 
with MS. On the other hand, measures of mood difficulties, such as of anxiety and depression 
have a questionable face validity, with many participants being able to guess, at least to some 
extent, the constructs being measured. However, attempting to utilise double-blinded 
procedures should be sought to minimise the influence of potential confounding variable, such 
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as various assumptions of emotional difficulties in those with MS that might be unintentionally 
projected by the researcher to the participant, or similar illness beliefs of the participants with 
MS affecting the ratings on mood questionnaires.   
 
Prevalence of Alexithymia in Multiple Sclerosis 
The key aim of this systematic review was to explore the prevalence of alexithymia in 
individuals with MS. Table 4 in appendix B reports percentages of alexithymia in all studies, 
according to the measures used and adopted cut-off scores. The data shows that the prevalence 
of alexithymia vary widely in individual studies, ranging from 10% to 53%. Overall, 277 out 
of 971 individuals with MS were classified as alexithymic which equates to 28.5% of the total 
sample. 
 
More specifically, studies (n = 10) which used TAS-20 to measure alexithymia, found the 
prevalence to range between 10% and 42.6%. The 42.6% prevalence was reported in the study 
by Chahraoui et al. (2008) who applied French cut-off value for presence of alexithymia which 
is five points lower than the cut-off value of 61+ used by the rest of the studies. The authors 
argue that the French cut-off value of 56+ is more appropriate for the French version of the 
instrument. Yet, as mentioned earlier, the original thresholds proposed by the Toronto team 
(Bagby et al., 1994) are also validated for the use with the French adaptation of TAS-20, which 
largely facilitate comparisons with other studies. It is also possible that the less restrictive 
French cut-off controls less well for type II error. The nine studies (n = 661; 64% females) 
which used the same cut-off score of 61 + for the presence of alexithymia, reported the 
prevalence to be significantly lower, ranging from 10% - 31.6%. It was found that 151 (23%) 




Only two studies used the BVAQ to estimate the prevalence of alexithymia in MS, showing 
discrepant levels of alexithymia, of 12% (n = 60; 58% females) in a study by Dulau et al. 
(2017), and of 53% (n = 189; 64% females) in a study by Gay et al. (2017). However, the study 
by Dulau et al., (2017) did not report their actual cut-off score. It is possible that they utilised 
a more restrictive cut-off score, since it was less than the 5th percentile of the matched HC score 
(-1.64 SD). This discrepancy highlights the importance of establishing specific cut-off scores 
of the presence of alexithymia for the BVAQ which can be universally applied for an ease of 
comparison across the studies.  Given the methodological and reporting limitations described, 
it appears that the most adequate estimate of prevalence of alexithymia in MS is the one based 
on the aforementioned nine studies, estimated at 23%, and ranging from 10% - 31.6%. Thus, 
levels of alexithymia seem to be indeed higher in those with MS, compared to rates of 
approximately 10%, previously reported in the literature on general population (Mattilaa et al., 
2006).  
 
Considering the limited power of all of these studies to detect effects and issues regarding 
sample representativeness and cut-off scores applied (as shown by the quality assessment in 
table 3, with quality criteria 1, 2, 5 and 6 being relevant to the assessment of prevalence) these 
results should be treated with caution. In particular, studies utilising much bigger samples of 
individuals with different clinical subtypes of MS and recruited from multiple settings should 







Relationship between Alexithymia, Depression and Anxiety in MS 
The second purpose of this review was to investigate the nature of the relationship between 
alexithymia, depression and anxiety in MS.  
 
Most studies (n = 8) employed the Beck’s Depression Inventory (BDI; Beck, Ward, 
Mendelson, Mock & Erbaugh, 1961) to investigate depressive symptoms in MS, with one study 
(Gay et al., 2017) utilising the Hospital Anxiety and Depression Scale (HADS; Zigmond & 
Snaith, 1983) and another study (Gay et al., 2010) using Depression Self-Rating Scale (DRS; 
Zung, 1965 ). All these measures were reported showing sound psychometric properties, with 
the BDI being one of the most frequently used measure of depression in MS and being validated 
in this population (Hind et al., 2016). Similarly, the HADS has been validated for use in MS 
population (Honarmand & Feinstein, 2009). Yet, some of the studies did not report whether 
the versions adopted for the local language were psychometrically assessed for use in MS 
populations.  
 
Seven studies investigated the relationship between alexithymia and depression in MS (Bodini 
et al., 2008; Cecchetto et al., 2014; Chahraoui et al., 2008; 2014; Dulau et al., 2017; Gay et al., 
2010; 2017), with Prochnow et al. (2011) reporting levels of depression and alexithymia but 
not exploring the relationship between the two. Data on depressive symptoms was reported for 
a total of 594 individuals with MS, with data missing for 3% (n = 16) of the total sample of 
610 individuals. The study of Dulau et al. (2017) did not report depressive symptoms at the 
individual level. The reported prevalence of moderate to severe depression varied between 
studies from 10% to 34.4%, with an overall estimate equating to 27%. Thus, 161 individuals 
out of 594 were reported as showing moderate to severe symptoms of depression. Although, 
this estimate needs to be taken with caution, since it is unclear whether the studies applied same 
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cut-off scores, the figure is similar to recently reported figures on depressive symptoms in MS. 
Boeschoten et al., (2017), in their systematic review of 58 studies with a total sample of 87,765 
patients with MS, estimated the prevalence of depressive symptoms in MS at 30.5%. The 
difference might be due to the limited size and representativeness of samples included in our 
studies, as well as potentially different cut-off scores, as highlighted by the quality assessment.  
 
Moderate to large positive relationships between alexithymia and depression scores were 
found. The TAS-20 total score correlated significantly with the BDI score in the study of 
Bodini et al. (2008), rho = .37, p <.004, Chahraoui et al. (2014), r = .27, p < .05, Cecchetto et 
al., (2014), r = .51, p = .004, and Gay et al. (2010), r = .50, p <.001. Gay et al. (2010) found 
that alexithymia and social support explain 56.7% of the variance in depression scores. 
Chahraoui et al. (2008) found depression and anxiety scores to predict 20% of variance in 
alexithymia scores. They further established a relationship between the TAS-20 subscales and 
depression score, and found moderate positive relationship between the DIF subscale and the 
BDI score, r =.31, p = .05. Likewise, Bodini et al. (2014) found, by means of a stepwise 
regression analysis that the DIF subscale was the strongest factor associated with depression. 
These findings suggest that those with MS who had difficulties identifying own feelings, had 
more depressive symptoms. Additional analysis of Bodini et al. (2014) indeed showed that 
individuals with MS and alexithymia (n = 8) were significantly more depressed (p <.007, d = 
1.06) than those without (n = 37). Same finding was reported by Chahraoui et al. (2014), where 
significantly higher levels of depression (p = 0.02, d = 0.71) were reported in those with 
alexithymia (n = 26), as opposed to those without (n=15).  
 
Contrary to these findings, Dulau et al. (2017) reported no relationship between alexithymia 
scores and depression in their sample of individuals with MS (r = .21, p = 0.12). Similarly, Gay 
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et al. (2017) reported no relationship between alexithymia scores and depression (r = .07, p > 
.05) in their study, further showing that depressed individuals with MS (n = 37) showed similar 
levels of alexithymia, compared to those who were not depressed (n= 128), F = (2, 186) = 1.36, 
p = .26. Interestingly, the only feature differentiating those two studies from the rest of the 
studies that found the relationship between alexithymia (as measured by the TAS-20) and 
depressive symptoms, was the measure used to assess alexithymia, namely the BVAQ. 
Although the majority of studies found a positive relationship between alexithymia and 
depression, more studies with larger representative samples are warranted to replicate these 
findings.  
 
Five out of 12 studies further investigated the relationship between anxiety and alexithymia, 
with four of them (Chahraoui et al., 2008, 2014; Dulau et al., 2017; Gay et al., 2010) employing 
the French adaptation of the State- Trait Anxiety Inventory (STAI; Spielberger, 1983) to 
investigate anxiety symptoms in MS, and one (Gay et al., 2017) utilising the French adaptation 
of Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) Both measures 
were reported showing sound psychometric properties (see Santangelo et al., 2016 for the 
STAI), with the HADS being validated for use in MS population (Honarmand & Feinstein, 
2009). Yet, it is unclear whether the French adaptations of the measure were psychometrically 
assessed for use in individuals with MS whose first language is French. We independently 
searched for such studies with no success. 
 
Data on anxiety symptoms was reported for a total of 431 individuals with MS. The study of 
Dulau et al. (2017) did not report anxiety symptoms at the individual level. The reported 
prevalence of state anxiety (i.e. temporarily induced anxiety by situations perceived as 
threatening, as measured by the STAI) ranged from 29.6% in the study by Chahraoui et al. 
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(2008) to 36.4%, in the study by Gay et al. (2010), with 60 out of 176 individuals with MS 
having this type of anxiety. The prevalence of trait anxiety (i.e. enduring, chronic anxiety as 
measured by the STAI) was similarly prevalent across three studies and equal to 43.6% in the 
study by Chahraoui et al. (2014), 43.8% in the study by Gay et al. (2010), and 44.3% in the 
study by Chahraoui et al. (2008), with 106 out 242 individuals with MS having this type of 
anxiety. Gay et al. (2017) found anxiety symptoms (as measured by the HADS) to be prevalent 
in 12.7% of their MS sample, with 24 out of 189 individuals having anxiety symptoms.  Thus, 
159 out of 431 individuals with MS had some anxiety symptoms, which equates to 36.8% of 
the total sample for which this data were reported. Although this estimate needs to be taken 
with caution, since the anxiety symptoms were measured by a small number of studies, with 
potentially different cut-off points, the figure is similar to the estimate found by Boeschoten et 
al., (2017). Their systematic review of 58 studies with a total sample of 87,765 patients with 
MS, estimated the prevalence of anxiety symptoms in MS at somewhat lower level of 34%. 
The difference might be due to the limited size and representativeness of samples included in 
a small number of studies, as well as potentially different cut-off scores, as highlighted by the 
quality assessment. 
 
Some studies found small to moderate relationships between alexithymia and anxiety, with the 
study of Chahraoui et al. (2014) reporting trait anxiety to be moderately correlated with 
alexithymia, r = .40, p < .01. These results are in line with the findings of Charhraoui et al. 
(2008) who found much higher levels of state anxiety in alexithymics with MS (F = 4.62, p = 
0.01) compared with borderline alexithymics (d = 0.70) and non-alexithymics (d = 0.89), with 
MS. Even bigger differences were found in relation to trait anxiety and alexithymia, (F = 6.13, 
p = 0.003), with alexithymics showing much higher ratings of trait anxious than borderline 
alexithymics (d = 0.93) and non-alexithymics (d = 0.84) with MS. Furthermore, at the whole 
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group level, ratings on the DIF subscale of TAS-20 correlated moderately with both, state (r 
=.43, p = .01) and trait (r =.43, p =.01) anxiety, whereas ratings on the DDF subscales correlated 
modestly with state anxiety (r =.28, p = .05), and moderately with trait anxiety (r =.31, p =.05). 
Further analysis revealed that depression, as well as state and trait anxiety predicted 20% of 
variance in alexithymia scores. These finding suggest that individuals with MS and higher 
levels of anxiety also present with difficulties in identifying and describing their emotional 
states. Also, the study of Gay et al (2010) have shown that alexithymia is a partial mediator of 
the relationship between trait anxiety and depression in MS. However, most recent studies do 
not entirely support those findings, with Gay et al. (2017) showing a very small relationship 
between alexithymia and anxiety symptoms, r = .18, p < .05. When they compared non-anxious 
individuals with MS to anxious ones, they found no significant differences in their levels of 
alexithymia, F(2,186) = 1.99, p = .14, suggesting that the presence of alexithymic traits is not 
higher in those with more anxiety symptoms in MS. Finally, the study of Dulau et al. (2017) 
found a small relationship between alexithymia levels and trait anxiety in MS which was only 
approaching significance (r = .22; p= .09).  
Although the majority of studies found a positive relationship between alexithymia and anxiety, 
similar to studies investigating the relationship between alexithymia and depression, more 
studies with larger representative samples and sufficient power to detect such relationships are 
warranted. This is crucial in order to produce a consistent pattern of findings in this area of 
research before we can conclude with confidence that the presence of alexithymic traits in 





Summary of findings 
The primary aim of this review was to draw together current data on alexithymia in individuals 
with MS, hypothesising that the prevalence of alexithymia will be heightened in people with 
MS.  
 
This review systematically evaluated twelve studies which investigated the construct of 
alexithymia in MS, with the estimated prevalence of 23%, and ranging from 10% to 31.6%. 
This is a more conservative estimate, based on nine out of those 12 studies, for reasons 
discussed in the result section of this review. It is still markedly higher compared to the 
prevalence of alexithymia in general population (approximately 10%), somewhat higher than 
in other neurodegenerative disorder, such as Parkinson’s disease (18% - 23.3%; Assogna et al., 
2016). Yet, it is noticeably lower than in other neurological conditions, such as TBI (30% - 
60%) or epilepsy (29% - 76%). Since several studies suggested that men score higher than 
woman on alexithymia questionnaires (Levant et al., 2006; Levant, Hall, Williams, & Hasan, 
2009), our results can, to some extent, reflect the composition of our total sample, which 
included 65.4% of females. It is possible that our estimate would be higher if more men would 
be included. This, however, would not be representative of the population of MS, which 
includes almost twice as much women (Milo & Kahana, 2010). Also, our total sample included 
predominantly individuals with RRMS (72%) and therefore, the results from this review are 
most probably best generalised to those with RRMS, and modest to moderate levels of 




Since research on alexithymia in MS, to date, has consisted of relatively small and mostly 
underpowered cross-sectional studies, conducted largely on individuals with RRMS with lower 
levels of disability, future research should consider including more individuals with chronic 
types of MS, which are characterised by higher levels of neurodegeneration and sustained 
disability that is likely to expand to social, emotional and cognitive impairments (Cotter et al., 
2016). The present review highlights the need for research investigating chronic types of MS 
in order to establish the extent to which the findings of our systematic review generalise to 
these particular individuals.  
 
The relationship between alexithymia, anxiety and depression in MS  
 
The secondary aim of this review was to evaluate whether alexithymia was associated with 
higher levels of anxiety or depression.   
 
The relationship between alexithymia, anxiety and depressive symptoms in MS warrants 
further assessment, and would potentially benefit from longitudinal investigation. It is 
encouraging that small to large relationships between alexithymia and depression or anxiety 
symptoms were found in the reviewed studies. Yet, these results should be treated as 
preliminary due to methodological limitations of the studies, discussed in detail in the result 
section of the review. In summary, the current review highlight the need for larger and more 
representative samples of individuals with MS, with sufficient power to detect such 
relationships. Thus, it would be recommended for future studies to obtain population-based 
data records from general practitioner-practices, hospital databases, health surveys, various MS 
societies and support groups, as well as reliable webpages, such as the web portal of the UK 
MS Register. Such a recruitment and selection process would potentially allow for some form 
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of random selection, at least at the level of invitation for taking part, and end up reaching a 
more representative number of individuals with MS; in terms of clinical types of MS, MS 
duration and severity, and sociodemographic variables.   
 
Strengths and Limitations of the Systematic Review  
The main strength of this review is a systematic and comprehensive search strategy and an 
assessment of risk of bias to aid interpretation of the findings. The tool used for an assessment 
of the study quality was adopted from an existing AHRQ tool and further amended in order to 
assess the methodological aspects of studies more precisely, as opposed to assessing their 
reporting quality. Although, the validity of this tool in its current form has not been 
investigated, the current guidance of the CRD suggests that AHRQ developed for the quality 
assessment of observational studies should be amended to suit the research being assessed 
(CRD, 2009).  
 
The potential limitation of the current review is that the quality ratings were carried out by one 
individual, with the other rater rating only 50% of the studies included. However, the inter-
rater reliability for the quality of those studies was relative high, with the percentage agreement 
in ratings equating to 68%. The study most probably is vulnerable to publication bias, since 
only the published studies were assessed in this review. We acknowledge the importance of 
including unpublished data in such reviews, yet most of the researchers that were contacted 
with regards to their published conference abstracts, did not reply to our request or did not have 
the data presented in a form of a manuscript. Also, this review was restricted to articles 







The rationale for this review stemmed from the evidence that alexithymia adversely impacts 
on adjustment to illness and/or recovery in various psychological conditions (Bach & Bach, 
1995; McCallum et al., 2003) and can hinder therapeutic outcomes (Lumley et al., 2007). Also, 
alexithymia is strongly linked to anxiety and depression in general population (Honkalampi et 
al., 2000). Since individuals with MS also present with high levels of depression and anxiety 
(Boeschoten et al., 2017), it was plausible that higher traits of alexithymia would be found. The 
present review highlighted that individuals with MS indeed reported more alexithymic traits, 
and the link between alexithymia, anxiety and depression symptoms in MS has been found in 
the reviewed studies. Thus, there will be individuals with MS who are at the higher risk of 
having alexithymia, as well as anxiety and depressive symptoms for which they might seek 
treatment.   
 
Such individuals need to be especially considered, in the context of neuropsychological 
rehabilitation and other psychological interventions, such as CBT or ACT which target mood 
difficulties in the context of adjustment to chronic illness. The effectiveness of these 
therapeutic approaches is reliant on close rapport with a therapist and a degree of insight into 
their internal emotional processes which, arguably those with high levels of alexithymia do not 
have. To best of our knowledge, studies on non-pharmacological or pharmacological treatment 
of alexithymia in MS are non-existent. Studies which explored non-pharmacological treatment 
of alexithymia were not carried out specifically on individuals with MS, but rather on 
individuals with various psychiatric disorders, such as anxiety and adjustment disorders, 
depressive disorders, and somatoform disorders to name a few (Grabe et al., 2008). For 
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instance, psychodynamic group therapy was shown to significantly reduce alexithymic 
features, as well as psychological distress in psychiatric inpatients (Grabe et al., 2008).   
As previously noted, the presence of alexithymia was associated with poor outcome in 
supportive therapy, as well as more traditional psychodynamic therapy (Ogrodniczuk, Piper & 
Joyce, 2011), with reduced access to one’s emotions, with difficulties identifying, 
differentiating and articulating own feelings, as well as lack of imagination typically seen in 
alexithymic patients. These presenting symptoms were considered to possibly reduce 
successful engagement in therapy. It is likely that some patients with MS will demonstrate 
similar presentation of symptoms in neuropsychological setting. Such clinical presentation of 
alexithymic features should be recognised and incorporated into psychological case 
formulation of the patient, by the clinical (neuro) psychologist who delivers the interventions. 
This might possibly prevent drop-out rates of such individuals and enhance therapeutic alliance 
with the group members and the psychologist.      
 
Further, there is some evidence showing that alexithymic symptoms can be reduced by other 
types of psychological approaches that can arguably be more easily incorporated into 
neuropsychological rehabilitation than psychodynamic group therapy. The controlled study of 
Beresnevaite (2000) aimed to reduce alexithymic traits and investigate whether this reduction 
would mediate the effects of treatment on health outcomes in 37 post cardiac arrest patients 
with elevated alexithymia scores. They were randomly allocated to either four months of 
weekly group therapy or two sessions of psychoeducation control group. The group therapy 
incorporated relaxation strategies, techniques aimed to increase emotional awareness and 
communication of one’s feelings, imagery, music therapy and psychoeducation/ strategies on 
nonverbal emotional expression. Significant reduction in the TAS scores were reported for the 
treatment group only, and this reduction in alexithymic symptoms predicted better 
44 
 
cardiovascular outcomes 24 months later. This study provides sound empirical evidence that 
alexithymia traits can be reduced and should be addressed by psychological treatments, as they 
can otherwise hinder health outcomes. Such psychological approaches aimed at reducing 
alexithymia traits should be developed and incorporated into neuropsychological interventions 
and, subsequently, adequately evaluated to expand the evidence base for the treatment of 
alexithymia in people with neurological conditions, such as MS.  
 
In terms of the pharmacological treatments of alexithymia, one study reported an improvement 
in alexithymic features in post-stroke depressed individuals after treatment with venlafaxine, a 
nonadrenergic and serotoninergic reuptake inhibitor (Cravello, Caltagirone, & Spalletta, 2009). 
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APPENDIX A: Quality Assessment Criteria of Observational Studies 
 
Table 1. 
Quality Assessment Criteria of Observational Studies 
 
1. Selection of 
the cohort is 
unbiased* 
The sample is likely to be representative of the target 
population. Type of recruitment strategy is less likely to 
introduce bias. 
Key baseline demographics (age, gender, years of 
education, ethnicity, setting, IQ) of the cohort are 
adequately specified (>4). 
Clearly determined inclusion criteria, including all of the 
following: type of MS, severity of MS, time since 
diagnosis, no co-morbid neurological or psychiatric 
conditions. For control group information: no neurological 
or psychiatric conditions,  
Yes 
The sample is less likely to be representative of the target 
population. Type of recruitment strategy is more likely to 
introduce bias. 
Key baseline demographics are less well specified (≤3) 
Meets all but one of the following: type of MS, severity of 
MS, time since diagnosis, no co-morbid neurological or 
psychiatric conditions. For control group information: no 
neurological or psychiatric conditions. 
Partially  
The sample is unlikely to be representative of the target 
population. Type of recruitment strategy is likely to 
introduce bias. 
Poor description of key baseline demographics (≤2). 
Some information is provided on inclusion and exclusion 
criteria but it is not clear, no consideration given to 
type/severity of MS and time since diagnosis. Would be 
difficult to replicate study on basis of details given. No 













This measure has been translated to a language spoken by 
the target population (i.e. MS) and has evidence of good 
validity and reliability in the study population. 
Psychometric properties of outcome measure of 
alexithymia are clearly reported or the reader is referred to 
an adequate source. 
Yes 
The measure has evidence of acceptable validity and 
reliability in other populations than MS or in a language 
not spoken by the target population. Psychometric 
properties of outcome measure of alexithymia are 
discussed less clearly and it is not possible to 
independently verify an adequate source. 
Partially 
The outcome measure has not been described in detail and 
have not undergone psychometric evaluation.  
No  











This measure has been translated to the language spoken 
by the target population (i.e. MS) and has evidence of good 
validity and reliability in the study population. 
Psychometric properties of outcome measure of depression 
are clearly reported or the reader is referred to an adequate 
source. 
Yes 
The measure has evidence of acceptable validity and 
reliability in other populations than MS or in the language 
not spoken by the target population. Psychometric 
properties of outcome measure of depression is discussed 
less clearly and it is not possible to independently verify an 
adequate source.  
Partially  
 
The outcome measure has not been described in detail and 
have not undergone psychometric evaluation.  
No 
 











This measure has been translated to the language spoken 
by the target population (i.e. MS) and has evidence of good 
validity and reliability in the study population. 
Psychometric properties of outcome measure of anxiety 
are clearly reported or the reader is referred to an adequate 
source. 
Yes 
The measure has evidence of acceptable validity and 
reliability in other populations than MS or in the language 
not spoken by the target population. Psychometric 
properties of outcome measure of anxiety is discussed less 




The outcome measure has not been described in detail and 
have not undergone psychometric evaluation.  
No 
 







G*Power 3.1.6 (Faul, Erdfelder, Lang & Bucher, 2007) was employed to 
calculate sample sizes needed for sufficient power. For correlational 
analyses it is required to recruit 614 individuals to detect a small effect size 
(r=0.1), 62 individuals to detect a moderate effect size (r =0.3), and 21 
individuals to detect a large effect size (r=0.5), with the statistical power of 
0.8 at an alpha level of 0.05. For group differences, it is required to recruit 
310 in each group to detect a small effect size (d=0.2), 51 to detect a 
moderate effect size (d=0.5), and 21 to detect a large effect size (d=0.8), 
with the statistical power of 0.8 at an alpha level of 0.05. 
A sample size is sufficiently large to detect small to 
moderate correlations (r=0.1-0.3) or group differences 
(d=0.2-0.5), with the statistical power of 0.8 at an alpha 
level of 0.05. 
Yes 
A sample size is sufficiently large to detect moderate to 
large correlations (r=0.3-0.5) or group differences (d=0.5-





A sample size is sufficiently large to detect only large to 
very large correlations or group differences with the 
statistical power of 0.8 at an alpha level of 0.05. 
No  









Examiners were not aware of the health status of the 
participants with MS during outcome assessment and 
scoring of measures. Participants with MS were blind to 
the research question.  
Yes 
 Either examiners who assessed outcomes were blind to the 
health status of the participants or the participants were 
blind to the research question. 
Partially 
 The study examiners who assessed outcomes were not 
blind to the health status of the participants. The 
participants were not blind to the research question. 
No 
 Examiner’s awareness of group membership is not 
reported or not described clearly enough to work out or no 





Analysis conducted is clearly appropriate to answer aims 
of the current review. Statistics, such as P-values e.g. effect 
sizes can be calculated if not reported. 
Yes 
 Analysis conducted is appropriate, with some limitations, 
e.g. not controlling for covariates or multiple comparisons. 
The findings are not reported in sufficient detail and effect 
sizes may not be calculated from data. 
Partially 
 Analysis conducted appears inappropriate to answer the 
research question and does not provide meaningful results. 
No 




* Note. Criteria 1, 2, 5 and 6 only were relevant to the first aim of the current review, with all of the criteria 







APPENDIX B: Decision Narrative in Quality Assessment 
 
Table 4. 




























7.   
Appropriate analytical methods 
  
 
Cecchetto et al. 
(2014)  
Partially:  









- Recruited from 
one hospital unit  











reported for Italian 
adaptation 
 




reliability of an 
Italian adaptation 
of TAS-20 in 
general population 





reported for Italian 
adaptation 
 
- Referred only to 
studies which used 
same measure in 
MS population 
 





properties in MS 
Italian population 





- MS = 30 
 
 
- Sufficient only 
to detect large to 




- No information 
provided 
N/A 



















- Key baseline 
demographics less 

























20 in general 
population (Bagby 
et al. 1994) 
 
N/A N/A No: 
 
- MS = 38 
 
- Sufficient only 
to detect large to 




- No information 
provided 
N/A 
- Descriptive analysis only  
 
Kuloglu et al. 
(2012) 
- Partially: 
- RRMS and SPMS 








- Recruited from 
one Neurology 










- Referred to study 
on reliability and 
validity of Turkish 
adaptation  of 
TAS-20 (details 
not discussed; 
Sayar & Gulec, 
2001) 
 
N/A N/A Partially: 
 
- MS = 60 
 
- Sufficient to 





- No information 
provided 
N/A: 















- English version 
of Sayar et al. 
(2001) paper not 
available 
Patil et al. 
(2016) 
Partially: 


























- Referred to study 
on reliability and 
validity of Spanish 




Sanches, 1996 not 
available 
N/A N/A No: 
 
- MS = 38 
 
- Sufficient only 
to detect large to 




- No information 
provided 
N/A 
- Descriptive analysis only 
 
Prochnow et al. 
(2011) 
Partially: Partially: 




-Referred to study 
on German test 
manual of BDI 
N/A No: 
 




- No information 
provided 
N/A 

























TAS-20 in general 
population (Franz 









- Sufficient only 
to detect large to 
very large effect 
sizes 
- Correlations between TAS-20 
and BDI not performed  
Bodini et al. 
(2008) 
Partially: 








- Recruited from 
one outpatient MS 
centre  


















reliability of an 
Italian adaptation  
of TAS-20 in 
general population 






reported for Italian 
adaptation 
 





properties in MS 
Italian population 




- MS = 58 
 
- Sufficient only 
to detect large to 





- No information 
provided 
Yes: 
- Adequate analysis to investigate 
group differences based on level of 
alexithymia in MS (ANOVA), and 
associations between variables 
(Spearman’s correlation and 
multiple logistic regression 
- Not stated whether data met 
assumptions for parametric tests 
- p-values and CI stated, effect 
















- Recruited from 
two outpatient MS 
centres- – those 
who had regular 
follow-up 
consultations 
approached by post 



















of TAS-20 in 
general population 
(Lous, Fremaux, 












properties in MS 
French population 




























- MS = 61 
 
- Sufficient only 
to detect large to 





informed about the 
study by the 
neurologist 
 
- The researcher not 
blinded, trained for 
the study, obtained 




- Adequate analysis of T1 and T2 
data using Wilcoxon test to 
account for nonparametric data. 
- Spearman’s correlation used 
adequately 
- p-values stated, effect sizes 










- Recruited from 









































- MS = 66 
 
- Sufficient to 





- No information 
provided 
Yes: 
- Adequate analysis to investigate 
group differences based on level of 
alexithymia in MS (ANOVA), and 
associations between variables 
(Spearman’s correlation and 
multiple logistic regression 
- Not stated whether data met 




- Key baseline 
demographics are 
poorly specified 
(only age and 
gender) 
- All required 
inclusion criteria 











properties in MS 
French population 
(e.g. Hind et al., 
2016) 
 












- p-values stated, effect sizes 
possible to calculate 
Fernandez-
Jimenez et al. 
(2013) 
- Partially: 





- recruitment from 
one university 
hospital – those 
who were coming 
for routine medical 
check-ups 



















reliability of an 
Spanish 
adaptation  of 
TAS-20 in MS  
N/A N/A Partially: 
 
- MS = 221 
 
- Sufficient to 





- Not stated whether 
participants were 
blinded to research 
question 
 
- The researcher not 
blinded obtained 




- adequate descriptive statistics 
(means and standard deviations) 
- investigation of prevalence of 








- All types of MS 
represented, wide 


















- MS = 115 
- Sufficient to 
detect large to 
Partially: 
 
- Participants were 




Adequate use of statistical 
methods of Pearson’s correlations 






























lived in the 
community 




- Inclusion criteria 
not stated 
 





French adaptation  
of TAS-20 in 
general population 
(Lous & Fremaux, 
1995) 
 




reliability of DRS 
(Zung et al., 1965) 
 





properties in other 
neurological 
conditions such as 
Parkinson’s 
Disease (Torbey et 



























- The researcher was 
not blinded- obtained 
written consent and 
participants medical 
information 
- Not stated whether data met 
assumptions for parametric tests 
- No correction for multiple 
comparisons was not applied 
- p-values stated, effect sizes 
possible to calculate 
Dulau et al. 
(2017) 
- Partially: 
- All types of MS 
represented, wide 
range of ages, 
those with higher 
disability status 





- recruitment from 
one MS clinic in 













French adaptation  






reported for French 
adaptation 
 
























- MS = 60 
 
-Sufficient to 
detect only large 





- No information 
provided 
Yes: 
- Accounting for nonparametric 
data 
- Bonferroni correction used for 
multiple comparisons 
Adequate use of Pearson’s 
correlation and multiple linear 
regressions  









- All required 
inclusion criteria 








properties in MS 
French population 
(e.g. Hind et al., 
2016) 
Gay et al. 
(2017) 
- Partially: 





- recruitment from 
three university 
hospitals 
- Key baseline 
demographics less 
well specified (e.g. 
education) 
















French adaptation  
of BVAQ in 
general population 












(Untas, et al. 
2009)  
 




reliability of HADS 

















et al. 2009)  
 

















- MS = 189 
 
Sufficient to 








informed about the 
study by the 
neurologist 
 
- The researcher not 
blinded, trained for 
the study, obtained 




- Appropriate use of ANOVA and 
Pearson’s correlations but no 
correction for multiple 
comparisons 
- Not clearly stated whether data 
met assumptions for parametric 
tests 
- p-values stated, effect sizes 
possible to calculate 
 
 







APPENDIX C: Prevalence of Alexithymia in Multiple Sclerosis 
 
Table 5.  
Prevalence of Alexithymia in Multiple Sclerosis 
 
Author(s) Sample Cut-off scores applied  Alexithymia  Borderline 
Alexithymia 
No Alexithymia 
Gleichgerrcht et al., 
(2015) 
RRMS = 38 
 
Toronto team cut-off values: 
Alexithymia: score: 61-100 
 
Borderline Alexithymia: score: 52-60 
 
No alexithymia: score: 20-51 
RRMS = 12 (31.6%) 
 
RRMS = 10 (26.3%) 
 
RRMS = 16 (42.1%) 
 
Cecchetto et al., (2014) RRMS = 30 
 
International cut-off values: 
Alexithymia: score: 61-100 
 
Borderline Alexithymia: score of 51-60 
 
No alexithymia score: 20-50 
RRMS = 3 (10%) 
 
RRMS = 4 (13.3%) 
 
RRMS = 23 (76.6%) 
 
Patil et al., (2016) RRMS = 38 
 
Toronto team cut-off values: 
Alexithymia score: 61-100 
 
Borderline Alexithymia score: 52-60 
 
No alexithymia score: 20-51 
RRMS = 12 (31.6%) 
 
RRMS = 10 (26.3%) 
 
RRMS = 16 (42.1%) 
 
Kuloglu et al., (2012) MS = 60 
 
North American cut-off value: 
Alexithymia score: 61-100 
 
No alexithymia: score 20-60 
MS = 14 (23.3%) 
 
No data MS= 46 (76.6%) 
 
Prochnow et al., (2011) MS = 35 
 
Toronto team cut-off values: 
Alexithymia score: 61-100 
MS = 9 (25.8%) 
 
MS = 13 (37.1%) 
 





Borderline Alexithymia score: 52-60 
 
No alexithymia score: 20-51 
Bodini et al., (2008) MS = 58 International cut-off values: 
Alexithymia score: 61-100 
 
Borderline Alexithymia score: 51-60 
 
No alexithymia score: 20-50 
MS = 8 (13.8%) MS = 13 (27.6%) MS = 37 (58.6%) 
Gay et al., (2010) MS = 115 North American cut-off value: 
Alexithymia: score: 61-100 
 
No alexithymia: score: 20-60 
MS = 27 (23.2%) No data MS = 88 (76.8%) 
Chahraoui et al., (2014) T1: MS = 66 
 
International cut-off values: 
Alexithymia score: 61-100 
 
Borderline Alexithymia score: 51-60 
 
No alexithymia score: 20-50 
MS = 19 (30.6%) 
 
MS = 19 (30.6%) 
 




MS = 221 Toronto team cut-off values: 
Alexithymia score: 61-100 
 
Borderline Alexithymia score: 52-60 
 
No alexithymia score: 20-51 
MS = 40 (18.1%) MS = 45 (20.4%) MS = 136 (61.5%) 
Chahraoui et al., (2008) MS = 61 French cut-off values: 
Alexithymia score: 56-100 
 
Borderline Alexithymia score: 45-55 
 
No alexithymia score: 20-44 
MS = 26 (42.6%) MS = 20 (32.8%) MS = 15 (24.6%) 
Gay et al., (2017) MS = 189 Alexithymia score 53-100 MS = 100 (53%) N/A MS = 89 (47%) 
Dulau et al., (2017) MS = 60 Alexithymia score was less than the 5th 
percentile of the matched HC score     (-
1.64 SD). 
MS = 7 (11.7%) 
 












APPENDIX D: Archives of Clinical Neuropsychology: Instructions for Authors 
 
PREPARATION OF MANUSCRIPTS 
 Manuscripts should be prepared carefully according to the American Psychological Association 
Manual of Style (6th ed). Italics are not to be used for expressions of Latin origin, for example, in 
vivo, et al., per se. Use decimal points (not commas); use a space for thousands (10 000 and above). 
Please avoid full justification, i.e., do not use a constant right-hand margin. Ensure that each new 
paragraph is clearly indicated. Present tables and figure legends on separate pages at the end of the 
manuscript. Manuscripts should be in their final form when they are submitted, so that proofs require 
only correction of typographical errors. All parts of the manuscript (except figures) should be 
double-spaced throughout and should be in a word-processing file. 
 
 Sections of the manuscript: Title page, Structured abstract, Keywords, Introduction, Methods, 
Results, Discussion, Funding, Acknowledgements, References, Tables, Figures (if not in a graphic-
type file like PDF, tif, eps, etc.) 
 
 Length of manuscript: While papers may be of any length required for the concise presentation 
and discussion of the data, succinct and carefully prepared papers are favored both in terms of impact 
as well as in readability. 
 
 General format: All sections of the manuscript must be double-spaced. Margins of 1 inch should 
be left at the sides, top, and bottom of each page. Number each page centered at the bottom (Title 
Page is 1). Italicize words and letters to appear in italics. Clearly identify unusual or handwritten 
symbols and Greek letters. Differentiate between the letter O and zero, and the letters I and l and the 
number 1. Each table and figure must be called out in the text. 
 
 Title page: The title should be short, specific, and informative. The first name, initial(s), and 
surname of each author should be followed by his or her department, institution, city with postal 
code, and country at the time the work was conducted. Email address, phone and fax numbers of the 
corresponding author should also be provided. Any changes of address may be given in numbered 
footnotes. The author to whom proofs and reprints should be addressed should be indicated. Please 
provide a running title of not more than 60 characters.  
 
 Abstract: The second page of every manuscript must contain the structured Abstract, which should 
not exceed 250 words. The Abstract should include each of the following sections: Objective: A 
brief statement of the purpose of the study, Method: A summary of the participants as well as 
71 
 
descriptions of the study design, procedures, and specific key measures, Results: A summary of the 
key findings, including specific results of significance testing to the extent that space allows, 
Conclusions: Clinical and theoretical implications of the findings as space allows. Abbreviations 
and reference citations should be avoided. 
 
 Key words: Up to six key words, which will appear after the abstract, should be included below the 
title, each separated by a semicolon (;). Keywords should be selected from the APA list of index 
descriptors, unless otherwise agreed with the Editor. Thus, please give them careful consideration. 
 
 Funding: Details of all funding sources for the work in question should be given in a separate section 
entitled 'Funding'. This should appear before the 'Acknowledgements' section. The following rules 
should be followed: The sentence should begin: ‘This work was supported by …’. The full official 
funding agency name should be given, i.e. ‘National Institutes of Health’, not ‘NIH’ (full RIN-
approved list of UK funding agencies) Grant numbers should be given in brackets as follows: ‘[grant 
number xxxx]’. Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers 
xxxx, yyyy]’. Agencies should be separated by a semi-colon (plus ‘and’ before the last funding 
agency).  
 
 References: This journal follows American Psychological Association Manual of Style (6th ed.) as 
a guide for style and citation. Authors are responsible for the accuracy of the references. Published 
articles and those in press (state the journal which has accepted them and enclose a copy of the 
manuscript) may be included. In the text, a reference should be cited by author and date. Not more 
than six authors may be cited per reference; if there are more than six authors, use et al in the in-text 
parenthetical citation. At the end of the manuscript, the citations should be typed in alphabetical 
order, with the authors' surnames preceding initials. References should include, in the following 
order: authors' names, year, complete title of the article, journal title, volume number, inclusive page 
numbers, and (for books only) name and address of publisher. The name of the journal should be 
italicized and appear in full. 
 
 Tables: Tables should be typed on separate sheets and numbered consecutively with numbers (i.e., 
Table 1, Table 2, etc). Tables should be self-explanatory and include a brief descriptive title. Tables 
can include note(s) that appear below the table. Note(s) usually include full definitions of 
abbreviations that appear in the table. Footnotes are also acceptable and are indicated by lowercase 





 Abbreviations: Try to restrict the use of abbreviations to those listed in the American Psychological 
Association Manual of Style (6th ed.) and to those abbreviations that appear as word entries in 
Merriam-Webster’s Collegiate Dictionary. Any word you intend to abbreviate should be spelled out 
at first occurrence. The first spelled out occurrence should be followed by the abbreviation in 
parenthesis. Standard units of measurement may be used without definition in the body of the paper. 
Acronyms formed from phrases are unacceptable. 
 
 Preparing the files: When preparing your final files, please present all sections of the paper in one 
word-processing file, excluding illustrations. If necessary, tables may be placed in a separate word-
processing file. When creating and/or editing your manuscript, use the document mode (or 
equivalent) in the word-processor program. Type the title, authors, and affiliations in the journal 
style (i.e., in upper and lowercase), with bold font for the title and authors. The text should be typed 
unjustified, without hyphenation (except for compound words) and at double line spacing. Headings 
should be typed as follows: main (section) headings in bold upper and lowercase; subheadings in 
italic upper and lowercase letters with the text beginning on the next line; sub-subheadings in italic 
upper and lowercase letters with the text continued on the same line. Indexing flags should not be 
included in the text. Enter only one space at the end of sentences and after commas, semicolons, and 
colons. No space should be inserted before these punctuation marks. Do not use lowercase l (ell) for 
1 (one) or O for 0 (zero). These may look interchangeable but they have different electronic values. 
Check the final copy of your paper carefully because spelling mistakes, inconsistencies, and errors 
will be faithfully translated into the typeset copy. 
 
 Supplementary data: is supporting material that cannot be included in the printed version for 
reasons of space and is not essential for inclusion in the full text of the manuscript but would 
nevertheless benefit the reader. It should not be essential to understanding the conclusions of the 
paper but should contain data that is additional or complementary and directly relevant to the article 
content. Examples:more detailed methods, extended data sets/data analysis, tables, or additional 
figures (including color). It is standard practice for appendices to be made available online-only as 
supplementary material. All text and figures must be provided in suitable electronic formats. All 
material to be considered as supplementary material must be submitted at the same time as the main 
manuscript for peer review. It cannot be altered or replaced after the paper has been accepted for 
publication, and will not be edited. Please indicate clearly the material intended as supplementary 
material upon submission. Also ensure that the supplementary material is referred to in the main 
manuscript where necessary, for example as "(see Supplementary Material)" or "(see Supplementary 
Figure 1)." Acceptable formats: a maximum of 5 files is acceptable to make up the supplementary 
data unit for an article. The maximum size per file should not exceed 2 MB (though text files should 
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be a great deal smaller), and files must be as small as possible so that they can be downloaded 
quickly. An HTML index page is usually created to link the supplementary data file(s) to the article. 
Please provide short (2-4 word) titles for each individual file---these will be used to create links to 
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Empirical Paper Abstract  
 
Objective: This study explored whether there were differences in emotion regulation abilities 
in individuals with different variants of Multiple Sclerosis, compared to individuals without 
MS. It was further investigated whether negative illness perceptions predicted emotion 
dysregulation in Multiple Sclerosis, independently of disease severity. Emotion regulation 
abilities and illness perceptions were also explored as potential mediators of the relationship 
between illness severity and quality of life.   
 
Method: Hundred and seventeen individuals with a diagnosis of Multiple Sclerosis and 55 
healthy controls took part in this study. The following self-reported measures were employed; 
the Difficulties in Emotion Regulation Scale, the Illness Perception Questionnaire-Revised, 
the World Health Organisation Quality of Life, and the Patient Determined Disease Steps.  
 
Results: Individuals with Multiple Sclerosis reported difficulties accepting their emotional 
distress which were to some extent predicted by strong illness identity and negative 
emotional responses to having Multiple Sclerosis, independently of illness severity, and 
regardless of the relapsing-remitting or chronic nature of Multiple Sclerosis. Beliefs 
regarding the consequences of Multiple Sclerosis were found to be the only partial mediator 
of the relationship between illness severity and quality of life.  
 
Conclusions: Given that nonacceptance of emotional distress was significantly higher in 
Multiple Sclerosis, and predicted by having strong beliefs about illness identity and negative 
emotional responses, there is a scope for psychological interventions to be effective in 
alleviating these difficulties.  
 





Different Variants of Multiple Sclerosis 
 
Multiple sclerosis (MS) is a chronic inflammatory neurological disease of the central nervous 
system (CNS) which is the leading cause of neurological disability amongst younger adults 
(Compston & Coles, 2008). Most people are first diagnosed with a relapsing-remitting form 
of MS (RRMS; O’Connor, 2002), which involves attacks (relapses) followed by periods of 
recovery (remission). Relapses occur when inflammatory cells attack the myelin of specific 
nerves. Remission occurs when inflammation subsides and symptoms reduce. Although 
symptoms may disappear completely during remission process, after several relapses there 
may be residual damage to the myelin, resulting in partial recovery only (Neild, 2006). Most 
people initially diagnosed with RRMS later develop secondary progressive MS (O’Connor, 
2002), characterised by a steady increase in disability, as symptoms do not disappear 
completely after a relapse. In the primary progressive MS, unlike in RRMS, the first 
(primary) symptoms are progressive. They get worse over time rather than appearing as 
sudden attacks (relapses). Symptoms may continue to worsen over time or may become 
stable. The hallmark of the chronic progressive forms of MS (CPMS), namely secondary 
progressive MS and primary progressive MS is the permanent loss of neural tissue (Neild, 
2006). 
 
The disease tends to affect not only physical health of MS sufferers but also cognitive and 
emotional functioning. While physical and cognitive impairments present in MS, such as 
restricted mobility, reduced executive control and slowed processing speed, have been 
extensively researched (Kalmar, Gaudino, Moore, Halper, & Deluca, 2008; Rao, 1995), less 
is understood about the nature of emotional difficulties present in MS. Multiple areas of 
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axonal demyelination are implicated in MS with many of the lesions arising in the white 
matter of the frontal brain regions (Brownell & Hughes, 1962). Prefrontal cortex, frontal and 
subcortical brain circuits have been implicated in the self-regulatory processes crucial not 
only to executive functioning (Stuss & Alexander, 2007) but are also likely to be involved in 
emotion generation and regulation processes (Ochsner & Gross, 2005). Since a great number 
of MS sufferers show cognitive dysregulation on executive function assessments, it is 
possible that emotion regulation abilities are similarly affected (Kalmar et al., 2008).  
 
Emotion Regulation in MS 
 
Emotion Regulation refers to a set of abilities and processes that allow for an awareness, 
understanding, monitoring and evaluation of affective states as they arise, together with 
employing various strategies to mould the inner experience of those states and to govern the 
outer expression of affect (Gross, Sheppes, & Urry, 2011). For instance, emotion regulation 
strategies, such as expressive suppression (involving active inhibiting of the overt 
manifestation of emotions in response to an emotional event) or cognitive reappraisal (entailing 
a modification of the subjective experience of emotions by changing the way one thinks about 
emotional event) have been found to impact on well-being, with individuals who routinely 
employ suppression reporting poorer life satisfaction and more depressive symptoms, 
compared to individuals who use reappraisal (Gross &John, 2003). 
 
Moreover, the significance of effective emotion regulation processes and strategies has been 
widely acknowledged in clinical settings due to the adverse consequences of emotion 
dysregulation on functioning and well-being. Emotion dysregulation contributes to increased 
severity of anxiety, depression, as well as post-traumatic stress disorder and schizophrenia 
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(Liverant, Kamholz, Sloan & Brown 2010, Van der Meer, Van’t Wout & Aleman, 2009; Tull, 
Barrett, McMillan, & Roemer, 2007). Emotion regulation is believed to be important for 
psychological adaptation to chronic illness, such as rheumatoid arthritis (Van Middendorp, 
Geenen, Sorbi, Hox, Vingerhoets et al., 2005), kidney disease (Gillanders, Wild, Deighan & 
Gillanders, 2008), as well as MS (Phillips, Saldias, McCarrey, Henry, Scott et al. 2009). It is 
also likely to decrease life satisfaction, reduce work effectiveness and adversely impact on 
interpersonal relationships (Gross and Munoz, 1995) (Garnefski, Koopman, Kraaij & ten 
Cate, 2009). Therefore, understanding the nature and cause of emotion regulation difficulties 
in chronic conditions such as MS is vital when designing interventions aimed at improving 
functional outcomes of those suffering from the disease. Moreover, treatment plans included 
in the NICE (186) clinical guidelines for the management of MS in primary and secondary 
care focus primarily on physical and cognitive rehabilitation. Therefore, more research is 
needed into the emotion regulation difficulties of individuals with MS in order to extend the 
evidence base in this area and to incorporate a wider range of emotion regulation 
interventions into psychological treatments offered to people with MS.   
 
In relation to MS, the incidence of emotion regulation difficulties has been reported for over a 
century, with first clinical accounts describing uncontrollable laughter, as well as a dissociation 
between the overt displays of affect and subjective mood reports in individuals with MS 
(Charcot, 1887; Surridge, 1969). Some of the symptoms of emotion regulation disturbances in 
MS involve pathological laughter and crying, unusual feelings of euphoria, emotional 
incontinence (disproportional exaggerated emotional expression), pseudobulbar affect 
(atypical expression of affect due to involvement of cortico-bulbar pathways), as well as 
emotional lability (dramatic shifts of mood; Feinstein, 2004; Finger, 1998; Rabins, 1990; 
Schiffer, 1990). Also, alexithymia which involves inability to identify own emotional states, 
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together with difficulties to delineate bodily sensations of emotions from actual feelings 
(Mikolajczak & Luminet, 2006), has been implicated in MS (Gleichgerrcht et al., 2015) and 
associated with emotion dysregulation (Swart et al., 2009).  
 
Most of abovementioned studies of emotion regulation in individuals with MS have 
employed symptom report or clinical observation to investigate the nature of emotion 
regulation processes in this disease. Nevertheless, it is essential to examine specific aspects of 
emotional appraisal, experience and perceived control as assessed by standardized measures. 
To date, only three studies (Phillips et al., 2009; 2014; Schirda, Nicholas & Prakash, 2015) 
have used standardised assessments to explore emotion regulation processes in MS. Phillips 
et al. (2009) measured emotion regulation strategies using the Emotion Regulation 
Questionnaire (ERQ, Gross &John, 2003) in 86 individuals with MS. The ERQ is comprised 
of two subscales measuring appraisal of emotions and expressive suppression of emotions It 
was found that the absence of reappraisal as a method of emotion regulation was associated 
with lower self-reported quality of life. Similarly, a study by Schirda et al. (2015) found that 
emotion dysregulation was a partial mediator in the relationship between trait mindfulness 
and quality of life in their sample of 95 individuals with MS.  However, it is not possible to 
deduce whether emotion dysregulation is more common in MS, as neither of these studies 
employed a healthy control group. Additionally, a broader range of emotion regulation 
strategies (than those measured by the ERQ) needs to be explored in order to enhance an 
understanding of these processes in MS. 
 
These limitations were addressed in another study by Phillips et al. (2014) who investigated a 
variety of emotion regulation strategies in 31 individuals with MS and 31 matched controls 
using the Difficulties in Emotion Regulation Scale (DERS, Gratz & Roemer, 2004). This 
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well-validated measure comprises multiple subscales designed to assess discrete emotion 
regulation processes, including acceptance of the emotion, acknowledgement and 
comprehension of the experienced emotional state, an ability to manage impulsive conduct in 
the context of negative affect, as well as an ability to employ flexible strategies to modify 
experienced emotions as required by the situational demands. It was found that individuals 
with MS reported more problems with emotion regulation than did control individuals, with a 
medium effect size (d = .68). A lack of interaction between the groups and DERS separate 
subscales, implies that different aspects of emotion regulation were similarly affected by MS. 
Interestingly the same emotion regulation measure was employed by Schirda et al. (2015) in 
their study on trait mindfulness, emotion regulation and quality of life. Yet, group differences 
in specific emotion regulation strategies were not possible to be explored due to a lack of 
control group.  
 
One of the main limitations of the previous studies on MS is the use of heterogeneous cohort 
of individuals with MS. It is important to differentiate between those two heterogeneous 
types of the disease, since RRMS is mainly inflammatory in nature, with symptoms of the 
disease exacerbating and diminishing, leading to partial or complete recovery, while the 
CPMS forms being characteristic of permanent nerve damage, loss (Neild, 2006) and 
subsequent worsening of symptoms. It is therefore possible that the severity of the emotion 
regulation difficulties in MS is affected by the form of the disease. If individuals with 
different variants of MS had different patterns of emotion regulation difficulties, this could 
have potential implications for symptom management as well as rehabilitation and therapy 
goals. Furthermore, only one of the previously discussed studies (i.e. Schirda et al., 2015) on 
emotion regulation in MS explored psychosocial factors that can potentially impact on 
difficulties in emotion regulation and be possible targets of psychological intervention. They 
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reported that higher levels of dispositional mindfulness were significantly associated with 
lower levels of emotion dysregulation. Yet, it is likely that other factors, such as individuals’ 
illness representations can adversely impact on emotion regulation in MS. 
 
Illness Representations in MS 
 
In the area of adjustment to chronic illness, many studies, including those on MS (e.g. Jopson 
and Moss-Morris, 2003), have utilised the Common Sense Model (CSM) of illness 
representations developed by Leventhal et al. (1984). The CSM proposes that the cognitive 
perceptions that individuals hold about their illness impact on their coping styles and 
emotional responding. This is a “parallel” processing model, meaning that both cognitive and 
emotional representations are formed simultaneously, in parallel and can have a direct effect 
at each other (Hagger & Orbell, 2003). In short, individuals who are diagnosed with a health 
condition, develop an organised set of beliefs about their illness. These beliefs or cognitions 
are defined as illness representations and include knowledge, experience, emotions, as well as 
illness-related perceptions (Skelton & Croyle, 1991). Studies have shown that the perceptions 
that individuals hold about their illness are not only a significant predictor of adjustment, but 
also levels of social dysfunction, self-esteem, fatigue, as well as various mood problems 
(Heijmans, 1998; Jopson & Moss- Morris, 2003; Murphy, Dickens, Creed, & Bernstein, 
1999). 
 
In the context of MS, few studies explored the illness perceptions of individuals with MS. 
Jopson and Moss-Morris (2003) employed a well-validated assessment tool of illness 
representations, the Illness Perceptions Questionnaire- Revised (Moss-Morris et al., 2002), 
and reported that beliefs about MS significantly affected people’s adjustment to MS. Poor 
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outcomes (i.e social dysfunction, role dysfunction, low self-esteem, fatigue,) were associated 
with strong illness identity (ascribing a label and an array of symptoms to MS), belief in 
serious consequences of MS, and its cyclical timeline, low understanding of MS, as well as 
low perceived personal control over MS. The cross sectional design of the study made it 
impossible to ascertain the actual direction of relationships between variables. Yet, the 
analyses controlled for MS severity which helped to show that the poor outcome did not 
simply arise from the severity of illness itself. Similarly, Vaughan et al. (2003) conducted a 
cross sectional study utilising the Illness Perception Questionnaire (Weinman et al., 1996) 
and reported that strong MS identity, serious consequences of MS and low control levels of 
control over MS correlated with poor outcome (i.e. physical functioning, self-esteem, anxiety 
and depressive symptoms). Spain et al. (2007) reported similar findings in the context of 
health related QoL, with same dimensions of illness representations as in Vaughan et al. 
(2003) being associated with reduced QoL in MS, namely illness identity, consequences and 
perceived control/cure. In the most recent study by Bassi et al., (2016) strong illness identity 
and negative emotional representations were linked to lower psychological well-being, life 
satisfaction, and hedonic balance in those with MS.   
 
Since MS is incurable, unpredictable and with substantial individual variation, it seems 
unsurprising that previous studies found poor outcomes in MS to be associated with less 
helpful illness perceptions. It is also reasonable to assume that people with MS will develop 
beliefs and cognitions that are either helpful or detrimental to regulating their emotional 
responses to symptoms and their everyday difficulties, although this has not been extensively 
investigated. However, no studies to date have explored the link between illness 
representations and emotion regulation abilities in MS more directly.  
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Finally, no studies to date have investigated the relationships between illness severity, 
emotion regulation, illness representations and quality of life of people with MS. There is 
evidence that MS severity is strongly associated with poor quality of life (Henriksson et al., 
2001), while social dysfunction is predicted by illness representations in MS (Jopson & 
Moss-Morris, 2003). Moreover, previous studies showed that problems with emotion 
regulation predicted well-being in a range of healthy and clinical populations, including MS 
(Gross & John, 2003; Phillips, Henry, Hosie & Milne, 2006, Phillips et al., 2009; Phillips et 
al., 2014). More recently, Schirda (2015) showed via a simple mediation model that emotion 
regulation partially mediated the association between mindfulness and quality of life. Since 
adaptive emotion regulation protects against mental health difficulties and predicts higher life 
satisfaction (for a review see Gross and Munoz, 1995), whereas helpful illness 
representations may enhance adjustment to chronic illness (Jopson & Moss-Morris, 2003), it 
is, therefore, important to further explore the indirect effects of emotional and psychosocial 
factors, such as emotion regulation and illness representations, on potential relationship 
between illness severity and quality of life.  
 
Rationale for the study 
 
To address the abovementioned gaps in the literature, the current study aimed to look at the 
use of a broad range of emotion regulation strategies (as assessed by DERS) by exploring the 
effects of different types of MS on emotion regulation abilities, namely relapsing-remitting 
MS and the chronic progressive forms of MS, as well as healthy controls. This study extends 
previous research in MS by further investigating whether illness representations developed by 
individuals with MS impact on how they regulate their emotions, even when controlling for 
the severity of their condition. Few previous illness representation studies discussed above, 
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have attempted to account for disease severity, making it problematic to conclude whether the 
relationship between emotion regulation and illness cognitions results in fact, from the 
severity of the condition itself. The final aim of the study is to test the possible mediating 
effect of emotion regulation and illness representations in the relation between MS severity 
and quality of life. This is the first study to explore the relationships between these variables 
in individuals with MS. 
 
The study will address the following research aims: 
 
1) To explore whether individuals presenting with different variants of MS, namely RRMS 
and CPMS, will have different emotion regulation abilities, as compared to individuals 
without MS (HC).  
 
2) To explore whether negative illness representations predict emotion dysregulation in MS, 
independently of disease severity.  
 
More specifically, it was hypothesized  that individuals who have a strong illness identity, 
a poor sense of control over their MS, strong emotional responses to their MS and believe 
their MS to have had detrimental consequences on their lives, will have more difficulties 
with emotion regulation, after controlling for the effects of disease severity. 
 
These cognitive dimensions of illness representations were chosen based on previous 
findings of Vaughan et al. (2003) and Spain et al., 2007 (discussed above) which showed 
that illness identity, perceived control and consequences are associated most with key 
outcome variables.  
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3) To explore emotion regulation and illness representations as mediators of the relationship 
between MS severity and quality of life in MS.  
 
More specifically, it was hypothesised that emotion regulation abilities and illness 
representations will be significant mediators of the relationship between MS severity and 






Participants with MS were identified via NHS Grampian MS register. In total, 570 individuals 
with MS were randomly selected and invited via letter to take part in the study. 117 individuals 
with MS gave their informed consent and completed the questionnaires (20.5% of the original 
sample). The majority of the sample had a diagnosis of RRMS (n= 79; 67.5%). Secondary 
Progressive MS was the next most frequent type (n = 29; 24.8%), followed by Primary 
Progressive MS (n = 9; 7.7%). Individuals with the two progressive MS types were combined, 
in the analysis, into one chronic progressive group (CPMS; n = 38) introduction. Ethical 
approval was granted by the NHS NRES South West - Cornwall & Plymouth Research Ethics 
Committee (REC) (see appendix E). The inclusion criteria were: McDonald criteria for MS 
diagnosis (McDonald et al., 2001), as assessed by a neurologist, including lesions present on 
MRI, 18-65 years of age to avoid confounding effects of developmental changes in emotional 
skills or emotional changes due to aging. Participants were excluded if deemed not to have 
capacity to consent, had a pre-morbid history of neurological disease (other than MS), 
traumatic brain injury, psychiatric or mood disorder, severe alcohol or drug abuse, were 
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undergoing a relapse during testing, had poor understanding of English that would negatively 
affect their ability to complete questionnaires or understand instructions, had current optic 
neuritis, or other severe visual impairment that would negatively affect their ability to 
satisfactorily complete measures. 
 
Fifty five healthy controls matched for age, gender and education were recruited from the 
general community via word of mouth, though collaboration with the University of Aberdeen 
Research Participant Panel and friends/relatives of the MS participants. The inclusion criteria 
were: 18-65 years of age. Participants were excluded if they had a pre-morbid history of 
neurological disease, traumatic brain injury, psychiatric or mood disorder, severe alcohol or 
drug abuse, poor understanding of English that would adversely impact on their ability to 
complete questionnaires or understand instructions, had severe visual impairment that would 
again negatively affect their ability to satisfactorily complete measures.   
 
Demographic information  
 
There were 76% females in the RRMS sample, 61% females in the CPMS sample, and 58% 
females in the HC sample. The groups did not differ significantly in terms of male-female ratio, 
χ2 (2) = 5.50, p = .064. Descriptive statistics are shown in table 1 below. A main effect of group 
on age was found, F(2, 169) = 3.64, p = .028, ηp
2 = .041. Bonferroni post- hoc analysis revealed 
that the CPMS group was significantly older than the RRMS group (p = .034, r = .28, 95% CI 
[0.25, 8.95],), but not the HC group (p = .034, r = .23, 95% CI [-0.26, 9.03]). The age difference 
between the RRMS group and the HC group did not reach significance either (p = 1, r = .01, 
95% CI [-3.65, 4.09],). The three groups did not differ significantly in estimated years of 
education, F (2, 169) = 2.61, p = .076, ηp
2 = .030. The mean time since clinical diagnosis (in 
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years) did not differ significantly between the MS groups, t(115) = 1.32, p = 0.189, r = .13, 
95% CI [-5.17, 1.04]. The MS severity mean score on a patient-rated variant of the Disease 
Steps measure (Hohol, Orav, & Weiner, 1995) for the RRMS group (M = 2.25) was 
representative of mild disability, whereas for the CPMS individuals (M = 5.24) was 
representative of moderate disability. A significant difference between the groups was found, 
t(52) = 8.64, p < .001, r = .65, 95% CI [-3.67, -2.30],  indicating greater MS severity in 























Age 47.3 8.67 (45.4- 49.2) 51.9 7.19 (49.5- 54.3) 47.5 10.8 (44.6- 50.4) 




14.5 3.33 (13.4- 15.6) 14.6 3.00 (13.9- 15.3) 15.7 3.26 (14.9- 16.5) 




12.3 8.16 (10.4-14.1) 14.3 7.46 (11.9-16.8) --- --- --- 




2.25 1.79 (1.85-2.65) 5.24 1.67 (4.69-5.78)     --- --- --- 
(PDDS 0- 8) n = 79 n = 38  





All four validated self-report measure were completed by participants with MS. Two of these 
measures were MS specific (i.e. The Patient Determined Disease Steps and The Illness 
Perception Questionnaire-Revised) and therefore not filled in by HC. HC completed the 
remaining three measures (the Difficulties in Emotion Regulation and the World Health 
Organisation Quality of Life).  
 
1) Brief background and demographic information: age of participant, gender, years of 
education, type of MS, date of first symptoms, date of diagnosis, and other neurological or 
psychiatric diagnosis. 
 
2) The Patient Determined Disease Steps measure (PDDS; Hohol et al., 1995) was used to 
assess MS severity. This questionnaire was specifically designed for an evaluation of 
functional disability and disease progression in MS, based primarily on ambulation. The 
PDDS is an ordinal rating scale comprising nine classifications: 0 = ‘Normal, mild 
symptoms or signs, mostly sensory’, 1 = ‘Mild Disability, noticeable symptoms, still 
minor’, 2 =‘Moderate disability, no gait problems, but other disabling symptoms’, 3 = 
‘Gait disability, significant gait problems’, 4 = ‘Early cane, intermittent use of cane’, 5= 
‘Late cane, cane-dependent’, 6 = ‘Bilateral support’, 7 = ‘Confined to wheelchair’ and 8= 
‘Bedridden’. Scores range from 0-8, and they are used to classify individuals according to 
disability level: a score of 0-2 indicates ‘mild disability’ with sensory symptoms and no 
walking limitation; a score of 3-5 indicates ‘moderate disability’ with walking difficulties 
and need for a cane; a score of 6-8 indicates ‘severe disability’ with a need for bilateral 
support or wheelchair or being bedridden (Gulick, Namey, & Harper, 2011). Inter-rater 
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reliability for PDDS was found to be excellent (kappa = .80) compared to a moderate result 
for the Expanded Disability Status Scale (EDSS) (kappa = .54) which is the most widely 
employed clinical measure of severity in MS (Kurtzke, 1983). A longitudinal study 
conducted by Hohol et al., 1999), which compared the PDDS and the EDSS for evaluation 
of MS progression, showed that the two scales delivered similar evaluations and were 
strongly associated with each other at baseline, and over time. These findings grant further 
support for validity of the PDDS and its use as a simple, practical tool for evaluation of 
disease progression in MS (Hohol et al., 1999). The internal consistency for this measure 
was acceptable (cronbach’s alpha = .79). 
 
3) Emotion regulation problems were investigated using the Difficulties in Emotion 
Regulation Scale (DERS; Gratz & Roemer, 2004). The DERS is a self-report questionnaire 
designed to evaluate 6 domains of emotion dysregulation using 36 items; 1) acceptance of 
emotion (nonacceptance), 2) the ability to inhibit impulses when experiencing negative 
emotional states (impulse control), 3) the ability to successfully direct behaviour towards 
targets and goals when distressed (goals), 4) the ability to be aware of own emotions 
(awareness), 5) having clarity about and understanding of emotions experienced (clarity) 
and 6) the ability to access and use emotion regulation strategies (strategies). Higher scores 
indicate greater emotion regulation difficulties. The total score rages from 1-5. 
Psychometric properties of the DERS were shown to be adequate (Gratz & Roemer, 2004). 
The DERS was selected over other emotion regulation measures due to assessing a wider 
range abilities believed to be crucial for effective regulation of emotions, such as 
acceptance of emotional responses and awareness rather than contrasting strategies. The 






4) The Illness Perception Questionnaire-Revised (IPQ-R; Moss-Morris et al., 2002) - This 
questionnaire will be used to measure participants’ various beliefs about their illness. The 
IPQ-R encompasses eight cognitive illness representations, including illness identity, 
cause, acute/chronic timeline, cyclical timeline, consequences, personal control, treatment 
control and illness coherence, and a single subscale measuring emotional 
representations/responses to illness (Moss-Morris et al., 2002). Illness identity and cause 
are divided into separate subscales. Remaining dimensions form a third subscale. Scores 
ranged from 0-5. Items were coded so that higher scores reflect stronger negative beliefs 
on a particular subscale. The IPQ-R has demonstrated good construct, criterion and 
known-groups validity (Moss-Morris et al., 2002). Although the participants with MS in 
this study completed the entire IPQ-R, only the subscales that related to the study’s 
hypothesis were included for the analyses. These subscales were: 
 
(1) Illness identity - ratings of the number of 14 symptoms that individuals with MS 
believed to be (or not) associated with their illness. For the purposes of the study, three 
additional symptoms commonly present in MS (speech distortions, numbness, 
clumsiness) were added to the scale, as done in previous research (Jopson and Moss-
Morris, 2003) giving a score range of zero to 17.  
(2) Personal control (6 items) - ratings of people’s beliefs about their own capability to 
control symptoms they experience (e.g. “What I do can determine whether my illness 
gets better or worse”). 
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(3) Treatment control (5 items) – ratings of people’s beliefs regarding the effectiveness 
of the prescribed treatment in controlling the illness (e.g. “The negative effects of my 
illness can be prevented (avoided) by my treatment”). 
(4) Consequences (6 items) – ratings of people’s beliefs regarding the adverse impact of 
their illness on their life and functioning (e.g. “My illness strongly affects the way 
others see me”). 
(5) Emotional representations (6 items) - ratings of people’s beliefs regarding their 
negative emotional responses to illness (e.g. “Having this illness makes me feel 
anxious”). 
The internal consistency for different subscales was acceptable ranging from 0.75 to 0.81. 
 
Quality of life was assessed using the self-rated World Health Organisation Quality of Life 
instrument (WHOQoL-BREF; Skevington, Lofty & O’Connell, 2004). This questionnaire 
assesses multidimensional aspects of quality of life delineated into four separate domains 
of psychological well-being, social relationships, physical health, and functioning in the 
environment, using 24 items. Higher scores are indicative of better quality of life, with 
scores ranging from 0-100. Adequate psychometric properties of the WHOQoL-BREF 
have been reported (Harper & Power, 1998). Since the WHOQoL-BREF has been found to 
be sensitive to physical impairments, social participation restrictions, activity limitations, 
and difficulties in functioning in day to day environment, it is recommended as a quality of 
life measure for MS population (Wynia, Middel, van Dijk, De Keyser, & Reijneveld, 2008). 
Moreover, the WHOQoL-BREF has been found to display adequate validity in MS by 
correlating with disability, depression and caregiver assessments of QoL (Alshubaili, 
Awadalla, Ohaeri, & Mabrouk, 2007). The internal consistency for different subscales was 




 Statistical Analysis  
 
Strategy for dealing with missing data 
Within the final sample, 2% of variables were missing. These data were missing entirely at 
random, as demonstrated by Little’s MCAR test. The 2% of missing values were replaced with 
predicted values using the expectation-maximisation (EM) algorithm. This statistical technique 
has been regarded as a reliable method for handling missing data (He, 2010). Cases were 
excluded on pairwise basis. One person with MS did not fill in their DERS and PDDS 
questionnaires. All participants with MS returned their IPQ-R questionnaires filled in, except 
for one person, and further one failed to rate the illness identity scale.  
 
Strategy for dealing with outliers 
 
Potential outliers were initially investigated using boxplots. Subsequently, a method of 
winsorising was used to deal with outlying data. This technique involves recoding outliers to 
the next lowest (or highest) score that cannot be classified as an outlying score. Z-scores were 
computed for each of the dependent variables in order to screen for existing outliers. Z-scores 
lower than - 3.29 and greater than + 3.29 were classed as outliers, as normally distributed data 
points are anticipated to fall within this range (Field, 2013). Fifteen outliers across the DERS, 
IPQ-R and WHOQoL-BREF were found and subsequently recoded. 
 
Exploratory Data Analysis 
 
Data was explored for normality, skew, kurtosis and homogeneity of variance. The 
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Kolmogorov-Smirnov test of normality was employed alongside QQ plots, histograms. Z-
scores were computed for skew and kurtosis values; skew score was divided by the standard 
error, kurtosis score was square rooted (Field, 2013). Resulting z-scores were considered 
significant if the score was greater than 2.58 (Clark-Carter, 1997). 
The three subscales of the DERS (impulse control, goals and clarity) did not meet the 
assumptions for parametric analysis. Successful square root transformations were conducted 
based on the histogram distributions (Clark-Carter, 1997). All subscales were subsequently 
transformed accordingly (Field, 2013) for further comparisons which enabled 
parametric analysis to be carried out. 
Group differences between CPMS, RRMS and HC in the multiple subscales of the DERS, 
WHOQoL-BREF and IPQ-R were examined by conducting separate mixed design analyses of 
variance (ANOVAs), followed up by separate simple effects analysis (one-way ANOVAs) to 
delineate group differences in individual subscales where interaction effects were observed. 
Sample size was determined by carrying out a power analysis using G*Power 3.1, with an 
alpha level of 0.05, and a medium effect size (f = .25). This led to a predictive total sample size 
(two MS groups and HC) of 179 with an actual power of .80.   
 
For the secondary research question, relationships of DERS scores with other measures were 
investigated using Pearson’s correlations, employing a significance level of p < .01 to account 
for multiple comparisons. Next, hierarchical regression analysis was used to address the extent 
to which illness representations predict difficulties in emotion regulation in the sample of MS 
participants. Hierarchical regression controlled for factors such as disease severity. Sample size 
was determined by carrying out a power analysis using G*Power 3.1, with an alpha level of 
0.05, and a medium effect size (f = .25). This led to a predictive total sample size (two MS 




For the final research question, multiple mediation analysis was carried out to investigate 
whether the relationship between illness severity and quality of life was mediated by emotion 
regulation and illness representations. PROCESS macro (Hayes, 2013) was employed for SPSS 
in order to apply bias-corrected nonparametric bootstrapping procedures (5000 resampling) to 
test the direct, indirect and total effects of illness severity of quality of life. Ma and Zeng (2014) 
showed, using Monte Carlo simulation via Mplus that would recommend a minimum sample 




Table 2 below provides a summary of descriptive statistics for each of the dependent measures 
















Table 2.  
Descriptive Information for Emotion Regulation, Illness Representations and Quality of Life 











M SD 95%CI M SD 95%CI M SD 95%CI 
DERSa 
Total score 1-5 
       
Nonacceptance 2.50 1.09 (2.25-2.75) 2.41 0.98 (2.09-2.73) 1.86 0.72 (1.67- 2.06) 
Goals 2.85 0.80 (2.67-3.03) 2.85 0.80 (2.57-3.14) 2.63 0.67 (2.45-2.81) 
Impulse 1.95 0.49 (1.85-2.07) 1.94 0.57 (1.75-2.13) 1.76 0.43 (1.64-1.87) 
Awareness 3.16 0.82 (2.98-3.35) 3.33 0.93 (3.03-3.64) 3.42 0.74 (3.23-3.63) 
Strategies 2.07 0.66 (1.92-2.22) 2.17 0.78 (1.91-2.42) 1.89 0.47 (1.76-2.01) 
Clarity  2.52 0.37 (2.44-2.61) 2.64 0.52 (2.48-2.82) 2.51 0.30 (2.43-2.59) 
Total 2.48 0.44 (2.39-2.58) 2.53 0.51 (2.36-2.70) 2.31 0.36 (2.21-2.41) 
IPQ-Rb 
Total score 1-5 
         
Personal Control 
 
3.17 .52 (3.06-3.29) 3.32 .65 (3.10-3.53) --- --- --- 
Treatment Control 
 
3.40 .46 (3.30-3.50) 3.48 .55 (3.30-3.66) --- --- --- 
Consequences 3.09 .65 (2.95-3.25) 3.56 .51 (3.39-3.73) --- --- --- 
Emotional 
Representations 
2.72 .75 (2.56-2.89) 2.87 .78 (2.56-2.89) --- --- --- 
Illness Identity 
Total score 0-17 
7.72 2.86 (7.07-8.36) 8.13 3.19 (7.08-9.18) --- --- --- 
Quality of Life 
Total score 0-100 
Physical 52.2 11.5 (49.6-54.8) 43.5 11.2 (39.8-47.2) 59.2 10.6 (56.3-62.0) 
Psychological 60.1 12.7 (57.3-62.9) 53.5 16.1 (48.2-58.8) 63.9 11.3 (60.8-66.9) 
Social 69.3 20.0 (64.8-73.8) 61.6 22.1 (54.3-68.9) 68.1 21.0 (63.1-74.5) 
Environmental 74.8 14.4 (71.6-78.1) 65.9 15.2 (60.1-70.1) 76.7 13.5 (73.1-80.4) 
Total 64.1 11.9 (61.5-66.8) 56.2 12.6 (52.3-60.0) 67.2 11.9 (63.9-70.4) 
 
 
Note. DERS = Difficulties in Emotion Regulation Scale, IPQ-R = Illness Representations Questionnaire 
Revised, WHOQoL-BREF = World Health Organisation Quality of Life  
a  Note that higher scores on DERS imply more difficulties with emotion regulation. 










Differences in Emotion Regulation Abilities between the MS Groups and the HC 
 
To explore whether individuals presenting with different variants of MS differed in emotion 
regulation abilities, as compared to HC, a 3 x 6 mixed-design ANOVA with six levels of DERS 
subscales (nonacceptance, goals, impulse, awareness, strategies or clarity) as the within-subject 
variable, and group category (RRMS vs CPMS vs. HC) as the between-subject variable was 
conducted. There was a significant main effect of group, F(2, 168) = 3.60, p < .001, ηp
2 = .041. 
There was no significant difference in overall ratings between participants with the RRMS and 
CPMS (p = 1, r = .03, 95%CI [-.25, .15]). There was also a significant main effect of subscale 
type F(5, 840) = 110.7, p < .001, ηp
2 = .397, with some subscales having higher ratings than 
others. Importantly, there was a significant DERS subscale type x group interaction, F(10, 840) 
= 3.67, p < .001, ηp
2 = .042. Post-hoc analyses using the Bonferroni method indicated that 
significant differences between the groups were found on the DERS nonacceptance subscale 
only; both the RRMS group (p = .001, r = .33, 95%CI [-1.05, -.23]) and the CPMS group (p = 
.025, r = .30, 95%CI [-1.04, -.52]) reported more difficulties accepting their emotions, 
compared to the HC group. No significant difference were found between participants with the 
RRMS and CPMS (p = 1, r = .04, 95%CI [-.37, .55]). Lack of interaction effects on other 
subscales of DERS indicate similar levels of other emotion regulation abilities in participants 
with different variants of MS and HC. Because participants with different variants of MS did 
not differ on other subscales of DERS, subsequent analyses are based on nonacceptance 
subscale of DERS only. Also, since there were no group difference between the RRMS and 









Relationships between DERS nonacceptance subscale and other variables 
 
Pearson product-moment correlations for the MS between DERS nonacceptance scores, MS 
severity, and illness perception scores were conducted. Prior to these analyses, scatterplots 
were graphed to assess whether there were linear relationships between the variables, important 
for meaningful interpretation of the correlation coefficient. Linear relationships were present 
for all variables.  
 
For the MS participants, the DERS nonacceptance scores correlated significantly with some 
subscales of IPQ-R, namely Illness Identity, r =.331, p < .001 (n = 115),  and Emotional 
Representations, r =.481, p < .001 (n= 116), indicating small to medium size effects (Field, 
2013), with Personal Control, r =.206, p = .013 (n= 116), approaching the more stringent p 
<.01 criterion. No significant correlations were found for Treatment Control, r =.105, p = .131 
(n= 116), Consequences, r =.118, p = .104 (n= 116), or MS severity, r =.069, p = .231 (n= 116).  
 
Further, supplementary analysis of group differences in illness representations in MS is 
included in appendix F (Descriptive data is reported in Table 2 above). In sum, the CPMS 
group rated their illness perceptions, on the whole, as significantly more negative than the 
RRMS group, apart from illness identity.  
 
Regression Analyses Investigating whether Illness Representations may contribute to 




In order to test the hypothesis that negative illness representations predict emotion 
dysregulation in MS, independently of MS severity, a series of hierarchical regression analyses 
was carried out with DERS nonacceptance as the dependent variable. Data met all the 
assumptions of regression analysis. The results of the regression analyses are summarised in 
table 3 below. The PDDS score was entered onto the first step to control for illness severity. 
The illness representation dimensions were then entered on the second step to investigate 
whether they contributed a significant percentage of the variance in emotion dysregulation 
when controlling for the severity of MS. 
 
Table 3.  
Hierarchical Multiple Regression of the Illness Representation  
Dimensions on the DERS Nonacceptance Variable Controlling for Severity (n= 115). 
 
 DERS nonacceptance s 
Step and predictors 
(1) Control Variable 




(2) Illness Representations 
Illness Identity   
β   .191* 
Personal Control   
β .049 




Emotional Representations  
β     .443** 
R2change .283 
 
* P < .05, ** P < .001. 
 
Taken together, the MS severity variable did not contribute significantly towards a proportion 
of the variance in DERS nonacceptance scores. On the other hand, the illness representation 
dimensions did significantly predict emotion regulation difficulties, independently of MS 
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severity, accounting for a unique 28.3% of the variance for nonacceptance scores. The β 
weights show that strong negative emotional responses to illness, t(108) = 4.91, p <.001, as 
well as a strong illness identity, t(108) = 2.13, p =.036 were the two significant predictors of 
emotion dysregulation in MS. The belief that MS has severe consequences and a poor sense of 
personal and treatment control did not significantly predict variance in DERS nonacceptance 
scores.  
 
Mediating effects of emotion regulation and illness representations on MS severity and quality 
of life.  
 
Supplementary data on group differences in quality of life is presented in appendix F, with 
descriptive statistics being included in table 2 above. In sum, the CPMS group rated their 
quality of life, on the whole, significantly lower than the RRMS group, as well as the HC 
group. The RRMS group and the HC group did not differ significantly in their overall ratings. 
 
The final aim of the current study was to explore emotion regulation and illness 
representations as mediators of the relationship between MS severity and quality of life in 
MS. It was hypothesised that emotion regulation abilities and illness representations will 
significantly mediate the relationship between MS severity and quality of life. 
 
No significant multicollinearity between predictors was found. Correlational analyses among 
predictor and outcome variables were conducted and are shown in table 4 below, with medium 
significant relationships found between the outcome variable WHOQoL-total score and the 
following predictors: MS severity, DERS nonacceptance, IPQ-R Illness Identity, 
Consequences and Emotional Representations subscales. These significant predictors were 
100 
 
further included into the mediation model. Since all four WHOQoL-BREF subscales correlated 
significantly highly with each other (see table 5 in appendix F of the supplementary material), 
they were merged together into WHOQoL-Total score in order to minimise the number of 
comparisons in the analysis. Therefore, there was only one outcome variable to be included 
into the mediation model. 
 
Table 4. 
Correlational Analyses of the Predictor Variables 


















n = 117 
DERS Nonacceptance 
-.360** 








n = 117 
IPQ-R Treatment Control 
.080 
n = 117 
IPQ-R Consequences 
-.415** 




n = 117 
Note. **Correlation is significant at the 0.01 level  
            *Correlation is significant at the 0.05 level 
 
Next, the multiple mediation analysis was carried out to test the hypothesis that emotion 
regulation and illness representations will mediate the relationship between MS severity and 
quality of life. The MS severity (PDDS) was entered as a predictor and WHOQoL-Total as an 
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outcome variable. DERS nonacceptance, IPQ-R Illness Identity, IPQ-R Consequences and 
IPQ-R Emotional Representation were entered into the model as potential mediators of the 
relationship between MS Severity and QoL. A model summary (i.e. linear regression) 
generated an adjusted R2 = .34, implying that the five predictors explained 34% of variance in 
WHOQoL-BREF ratings, with the model reaching statistical significance, F (5,109) = 11.3, p 
< .001.  
 
Significance of direct and indirect effects was determined based on the lower and upper 95% 
confidence interval not including zero. The total effect of the relation between MS severity 
(PDDS) and QoL (WHOQoL-BREF; before accounting for the effect of emotion regulation 
and illness representations was significant, (B = -2.19, SE = .50, p < .001, 95% CI [-3.17, -
1.20]), such that higher levels of MS severity were associated with lower levels of QoL. 
Further, the direct effect of the relation between MS severity (PDDS) and QoL (WHOQoL-
BREF) remained significant, (B = -1.27, SE = .52, p=.02, 95% CI [-2.30, -0.24]) after 
controlling for emotion regulation (DERS nonacceptance) and illness representations (Illness 
Identity, Consequences and Emotional Representations). As reported in table 6 below the total 
indirect effect via the mediators (the difference between the total and direct effects) was 
significant (point estimate of -.92, 95% CI [-1.69, -0.30]). The specific indirect effects in this 
mediation analysis are reported below in Table 6. IPQ-R Consequences was the only significant 
mediator of the relationship between MS severity and QoL in MS. This suggests that strong 
negative beliefs about the consequences of MS mediate the relationship between MS Severity 
and QoL. Since the direct effect of MS Severity on QoL remained significant in this model, the 
IPQ-R Consequences was a partial mediator of the relationship between severity of MS and 







Specific Indirect Effects of Potential Mediators 
 
 Point estimate of 










DERS Nonacceptance -.08 .116 -.41 0.09 
IPQ-R Illness Identity -.20 .145 -.59 0.01 
IPQ-R Consequences * -.54 .294 -1.25   - 0.07 
IPQ-R Emotional Representations -.10 .110 -.46 0.02 
Total Indirect Effect * -.92 .345 -1.69   - 0.30 
 
Note. BCBCI = Bias corrected bootstrapped confidence interval with 5000 samples 















            B = .032 (.045)      
  
 
           B = -2.50 (1.09)* 
                                   
                                                                  










MS Severity  
 









Quality of Life 
 






     B = -3.82 (1.93)*  
 















Figure 1 Mediation effects of Nonacceptance of Emotions (as measured by DERS = Difficulties in Emotion 
Regulation Scale) and Illness Representations (as measured by IPQ-R = Illness Representations Questionnaire 
Revised) on the relationship between Illness Severity (as measured by PDDS = Patient Determined Disease Step) 
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and Quality of Life (as measured by WHOQoL-BREF = World Health Organisation Quality of Life) in MS. All 
figures represent uncorrected path Beta- coefficients, with the SE listed in parenthesis. The results indicate that the 
relationship between MS Severity and Quality of Life in MS was reduced when mediators were accounted for. 
Bootstrapping indicated that the beliefs about the Consequences of Illness was the only significant and partial 
mediator of the relationship between Illness Severity and Quality of Life.  
Note: ** significant at the 0.01 level,  * significant at the 0.05 level 
Discussion  
 
The primary aim of this study was to investigate whether there are differences in emotion 
regulation strategies employed by people with relapsing-remitting MS and chronic progressive 
MS, as compared to healthy controls. It was further inquired whether illness representations 
developed by individuals with MS impact on how they regulate their emotions while 
accounting for the severity of their MS. The final aim was to explore the mediating effect of 
emotion regulation and illness representations in the relationship between the severity of MS 
and self-reported quality of life in MS.  
 
Group Differences in Emotion Regulation in MS 
 
It was found that both MS groups, the RRMS group and the CPMS group reported moderate 
difficulties in accepting their feelings of distress, compared to the HC group. However, no 
significant differences on the DERS Nonacceptence subscale were found between the MS 
groups, implying similar levels of difficulty with accepting emotional distress in individuals 
with different variants of MS. Interestingly, a lack of other significant differences on the rest 
of DERS subscales between individuals with MS and healthy controls suggests that other 
processes of emotion regulation are relatively intact in MS. These findings are partially 
consistent with previous literature. The study of Phillips et al. (2014) found that individuals 
with MS, as compared to HC, reported overall more difficulties with emotion regulation, as 
measured by the DERS. Yet, the different emotion regulation processes appeared to be 
similarly affected, as indicated by no significant group differences on the DERS subscales. 
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However, it is likely that the results of Phillip’s study are underpowered due to a small sample 
size (31MS, 31HC). When exploring the reported mean statistics, the biggest mean difference 
between the MS and HC group in Philip’s et al. (2014) study was, similarly to this study, on 
the Nonacceptance subscale of the DERS. Another study (Yule, 2013) on emotion regulation 
in chronic neurological condition, namely stroke (50 stroke, 45 HC), also found significantly 
higher difficulties with nonacceptance of emotions (and impulsivity) in stroke survivors, as 
measured by the DERS. Yet, the sizes of these effects are not reported. Interestingly, 
nonacceptance of emotions as indicated on the DERS has been reported previously as one of 
the core difficulties in alexithymia (Pandey et al. 2008), which is also found in MS 
(Gleichgerrcht et al., 2015). Given unpredictable occurrence and/or progression of symptoms 
in MS, it is not surprising that those with this chronic and, in most cases, progressive 
neurological condition struggle to tolerate their distress.  In fact, there is evidence, particularly 
in the ACT literature, that non-acceptance of experiences, including emotional states, has a 
negative impact on functional/adjustment outcomes across conditions, such as chronic pain 
(McCracken & Eccleston, 2003); diabetes (Greg, Callahhan, Hayes, & Glenn-Lawson, 2007), 
epilepsy (Lundgren, Dahl, Yardi, & Melin, 2008), as well as MS (Pakenham & Fleming, 2010). 
Thus, addressing non-acceptance of emotional experiences in MS might be important in 
improving coping and functioning in MS.  
 
Encouragingly, no differences between the MS groups and HC were found on other emotion 
regulation abilities. This was the first study to date that explored whether the severity of 
emotion regulation difficulties in MS was affected by the form of MS. While one could 
speculate whether the unpredictable trajectory of RRMS (with fluctuating functioning and 
recovery) or permanent neuronal loss of CPMS (resulting in progressive disability) is more 
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likely to lead to emotion regulation problems, it appears that the variant of MS alone is not 
indicative of specific emotion regulation difficulties.  
 
 
Negative Illness Representations as Predictors of Emotion Dysregulation in MS 
 
It was specifically hypothesized that individuals with MS who had a strong illness identity, a 
poor sense of control over their MS, strong emotional responses to their MS and believe that 
their MS has detrimental consequences on their lives, will have more difficulties with their 
emotion regulation.  
 
First, the differences between the RRMS group and CPMS group in illness representations 
were explored, as this was not previously explored in the literature. It was found that overall, 
the CPMS group held more negative beliefs about their illness than RRMS group. However, 
both group also reported similar levels of illness identity. In other words, both groups were 
ascribing similar number of physical symptoms they experience to having MS, despite those 
with RRMS having lower levels of MS severity. One may assume that those with CPMS would 
develop a stronger and more negative identity of their illness than those with RRMS, simply 
because CPMS is associated with higher levels of progression and disability (Lucchinetti & 
Parisi, 2006).  
 
In the context of the study’s hypotheses, some aspects of Illness Representations did 
significantly predict 28.3% of the variance in DERS nonacceptance scores, independently of 
MS severity. The results indicate that those individuals with MS who have a strong and 
negative illness identity, as well as strong negative emotional responses to having MS, will 
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experience more difficulties in accepting their distress. Contrary to our hypothesis, having a 
poor sense of control, as well as holding negative beliefs about the consequences of having MS 
does not appear to contribute to nonacceptance of one’s negative emotional states. This is the 
first study which demonstrates that the way people with MS perceive and think about their 
illness is linked with their emotion regulation abilities, to some extent. It is therefore possible 
that helping people address their negative perceptions and reactions to their illness will result 
in more effective emotion regulation.    
 
These results add to previous evidence on emotion regulation in MS. Although this type of 
research is still in its infancy, there is evidence that factors such as low levels of dispositional 
mindfulness are linked to higher levels of emotional dysregulation in MS (Schirda et al., 2015). 
The current study shows that other psychosocial factors such as negative beliefs about one’s 
illness are also likely to be associated with some aspects of emotion dysregulation in MS, 
mainly nonacceptance of one’s distressing emotions. These findings also help to ascertain that 
problems with emotion regulation in MS do not simply arise from the severity of MS, i.e. 
problems with ambulation. Thus, it is important in future studies to control for factors such as 
MS severity.  
 
Moreover, in the context of MS, illness representations have been mainly explored in relation 
to adjustment and outcome (Jopson & Moss- Morris, 2003; Vaughan et al., 2003), showing that 
negative illness representations are associated with poor functional outcomes, and difficult 
adjustment. The fact that high illness identity and negative emotional responses to having MS 
predicted non-acceptance of distress (as measured by DERS) further supports the 
aforementioned idea that intolerance of distress in MS might stem from difficulty coping and 
adjusting to having this unpredictable condition. A number of outcome measures has been 
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incorporated to study adjustment in MS, including sickness impact, mood, QoL, self-esteem, 
social and occupational adjustment, as well as fatigue levels (e.g. Jopson & Moss-Morris, 2003; 
McCabe et al., 2004; van Kessel et al., 2008; Vaughan et al., 2003). While these 
biopsychosocial factors are undoubtedly important for adequate adjustment to chronic illness 
such as MS, we would argue that emotion regulation processes and strategies should be 
incorporated into current models of adjustment to MS (such as e.g. working model of 
adjustment to MS by Dennison et al., 2009). This is so, because emotion dysregulation has 
been linked to lower quality of life in MS (Schirda et al., 2015), severity of anxiety and 
depression (Liverant et al., 2011), as well as shown to be an essential psychological adaptation 
to other chronic illnesses, such as rheumatoid arthritis (Van Middendorp et al., 2005), kidney 
disease (Gillandres et al., 2008), and Juvenile Idiopathic Arthritis (Garnefskia, Koopmanb, 
Kraaijb & Catec, 2009). Thus, future studies should explore more closely the emotion 
regulation processes (using e.g. DERS) and strategies (using e.g. ERQ) used by people with 
MS in relation to various aspects of outcome and adjustment.    
 
The results of this study, so far, have shown that individuals with MS have difficulties with 
nonacceptance of their negative emotional experiences which are to some extent predicted by 
strong illness identity and negative emotional responses to having MS, independently of MS 
severity, and regardless of the relapsing-remitting or chronic nature of the MS.  
 
Emotion Regulation and Illness Representations as Mediators of the Relationship between MS 
Severity and Quality of Life 
 
Lastly, we hypothesized that emotion regulation abilities and illness representations will be 
significant mediators of the relationship between MS severity and quality of life. Since there 
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were no significant MS group effects on Emotion Regulation and Illness Representation 
measures, it was decided that the mediation analysis would be conducted on the entire MS 
sample. 
  
We found that having higher MS Severity (PDDS), struggling to accept negative emotions 
(DERS Nonacceptance), as well as holding more negatives beliefs about own illness is 
associated with poorer quality of life in MS. More specifically, ascribing more symptoms to 
having MS (IPQ-R Illness Identity), believing MS to have serious consequences (IPQ-R 
Consequences) and having more negative emotional responses to having MS (IPQ-R 
Emotional Representations) is linked with reduced self-rated quality of life. Although, it was 
found that these five constructs predicted 34 % of variance in quality of life scores, only beliefs 
regarding the consequences of MS were found to be the partial mediator of the relationship 
between MS severity and quality of life. Thus, there will potentially be other factors that affect 
the association between MS severity and quality of life that need investigating.  
 
MS Severity, particularly in the context of ambulatory impairment, is a common characteristic 
of MS, especially in its progressive forms. It has serious consequences for functioning of those 
with the disease and these results provide further support for previous findings of the strong 
relationship between MS severity (motor impairment) and reduced QoL in MS literature. It is 
important to explore other psychosocial factors that can mediate this relationship, as those with 
similar motor disturbances in MS might report reduced QoL for reasons other than the motor 
difficulties themselves. As demonstrated by this study, the beliefs about the consequences of 
MS appeared to contribute to this relationship. In other words, people with MS whose 
ambulation problems prevent them from having an adequate QoL, might have developed 
negative beliefs about the consequences of their MS which further contributes to their reduced 
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QoL; for instance their might think that their walking difficulties are ‘too severe’ to attempt 
leaving the house which could result in restricted social participation and reduced QoL.  It is 
somewhat surprising that other aspects of Illness Representations ( as measured by Illness 
Identity, Emotional Representations and Personal and Treatment Control subscales of the IRQ-
R) do not further contribute to this relationship, as previous literature reported these aspects of 
Illness Representations to be associated and/or predict various health outcomes and adjustment 
to MS (Jopson & Moss- Morris, 2003; Vaughan et al., 2003). Also, emotion regulation 
difficulties in the form of the nonacceptance of emotions did not contribute to the relationship 
between MS Severity and QoL. This is contrary to previous evidence that emotion regulation 
difficulties predicted poorer psychological and social quality of life in MS (Phillips et al., 
2014). It might be that moderate difficulties with accepting distressing feelings are not in itself 
severe enough to contribute to this relationship, or that there are other additional psychosocial 
factors, such as mood difficulties, that play a role. It might be that high levels of anxiety or 
depression resulting to some extent from the severity of MS might further mediate the 
relationship between the severity and reduced QoL. Thus, future studies, should explore the 
potential mediating impact of heightened levels of anxiety and depression, which are reported 
to be high in people with MS (Boeschoten et al., 2017)   
 
Taken together, the findings of this study show that individuals with MS have moderate 
difficulties with nonacceptance of their emotional states, irrespectively of MS variant, with 
other emotion regulation abilities being unaffected, as compared to HC. These difficulties are 
to some extent predicted by having strong illness identity and negative emotional responses to 
having MS, independently of the severity of their illness. The beliefs about the negative 
consequences of having MS partially mediated the relationship between MS severity and 









This study found moderate difficulties in one particular aspect of emotion regulation, namely 
non acceptance of distress, in MS, and these difficulties were associated with reduced self-
reported QoL. Although further research is warranted to assess the prevalence of emotion 
regulation difficulties in MS, the findings of this study are encouraging in a sense that emotion 
regulation difficulties might not be very severe within MS population, and possibly not 
dependent on MS type. However, this is surprising considering high levels of depression and 
anxiety in MS, and the findings that depression mediated emotion regulation difficulties in one 
study on MS (Phillips et al., 2014). The assumptions that high levels of depression and anxiety 
in MS result, at least to some extent, from poor emotion regulation processes and maladaptive 
strategies is still worth exploration, although our findings do not point to severe emotion 
dysregulation in our sample of MS participants. Since psychological interventions are 
commonly conducted with individuals with MS and comorbid cognitive impairments or mood 
disorders (such as depression and anxiety) that further impact on functioning, rather than 
selective emotion regulation difficulties, it might be more beneficial to explore emotion 
dysregulation and emotion regulatory strategies in a sample of MS individuals who also meet 
criteria for anxiety/depressive disorder or cognitive impairments, rather than excluding them 




The National Institute of Health and Clinical Excellence (NICE, 2014) guidelines on the 
management of Multiple Sclerosis in adults in primary and secondary care recommend having 
psychologists as integral members of the neurological rehabilitation services. More 
specifically, different variants of Cognitive Behavioural Therapy (CBT) are recommended for 
the treatment of depression and/or anxiety. Also, the Matrix: A Guide to Delivering Evidence- 
Based Psychological Therapies in Scotland (Matrix, 2015), for neurological disorders, 
recommends CBT adjustment group intervention to reduce distress in MS. Yet, there are other 
therapeutic approaches addressing difficulties with emotion regulation, such as Dialectical 
Behaviour Therapy (DBT) and Acceptance and Commitment Therapy (ACT; Aldao, Nolen-
Hoeksema & Schweizer, 2010) which might prove effective in MS population. Therefore, more 
research looking at efficacy and effectiveness of other therapeutic approaches is warranted and 
timely.  
 
Given that, in the current study, nonacceptance of negative emotions was significantly poorer 
in MS, and predicted by having strong beliefs about illness identity and negative emotional 
responses, it is possible that some aspects of ACT might be effective in addressing these 
difficulties. ACT puts emphasis on exploring people’s directions for valued living despite their 
illness, identifying current unworkable actions in the form of cognitive fusion (i.e. when beliefs 
about illness identity and consequences of MS are treated as facts) that can lead to experiential 
avoidance (e.g. participating in less activities to avoid unpleasant feelings of 
disappointment/embarrassment), and potentially exacerbating difficulties accepting such 
negative emotional states. ACT encourages committed actions in directions that are valued by 
the individual (Harris, 2009) which is an approach commonly adopted by specialist 
neuropsychological rehabilitation services which attempt to identify workable goals with their 
clients with MS to increase their functional outcomes and  QoL. It would be interesting to see 
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whether this type of approach could improve emotion regulation by reducing the impact of 
illness representations in MS. Our results indicate that the relationship between MS severity 
and QoL is mediated by the negative beliefs about the consequences of MS. Again, ACT might 
prove beneficial in improving psychological flexibility and reducing narrow and/or rigit 
behaviours that contribute to poorer QoL in people with MS.  
An ACT oriented approach to rehabilitation in MS, could affect an understanding of MS related 
emotional and psychosocial difficulties in all MDT members, and their subsequent responses 
to clients. In the context of chronic and unpredictable illness, such as MS, certain thoughts, 
beliefs and emotional responses are inevitable. In certain instances, active therapeutic efforts 
to challenge, change or discourage these experiences via e.g. CBT might prove unproductive 
or be simply unrealistic. Although the abovementioned applications of ACT in MS population 
are highly speculative at this stage, and it is important not to ‘get ahead of the data’, the need 
for further research into psychological interventions that could improve emotion regulation, 
illness representations and QoL in MS cannot be underestimated. Since the DERS has been 
shown to display sensitivity to change over time (Fox, Axelrod, Paliwal, Sleepe & Sinha, 
2007), it can be utilised in future studies as an outcome measure of emotion regulation abilities 
and to monitor the effectiveness of psychological interventions in MS.   
 
Limitations and suggestions for future studies 
 
Most of the limitations and suggestions for future studies have been already discussed 
throughout the previous sections of this discussion. The main limitation of this study, and most 
psychological research in MS, is its cross-sectional design. Thus the true direction of the 
relationships between investigated variables cannot be guaranteed. Future longitudinal studies 
and interventions targeting emotion dysregulation and challenging or reducing the effects of 
113 
 
illness and symptom beliefs would prove key in further consolidating these results. Also, 
multiple assessments of emotion regulation processes and strategies, as well as social 
functioning, at different points in time could assist researchers and clinicians in  to determining 
the viable and changing trajectory of MS effects on emotional and psychosocial functioning. 
 
As abovementioned, other potential contributing factors, such MS severity, mood disorders 
(e.g. depression or anxiety), brain volume loss, levels of social support should be investigated 
when looking at differences in emotion regulation in MS, independently of MS type.  
 
Although, the severity of MS was significantly higher in the CPMS group, compared to RRMS 
group in this study (i.e. moderate and mild respectively), there were significant individual 
differences in severity within the groups. Moreover, the PDDS measure of MS severity is based 
solely on ambulation. It might be useful to incorporate other indicators of severity, such as 
levels of fatigue, spasticity, pain, mood and/or cognitive dysfunction. Given the extensive 
nature of MS deficits, more comprehensive disease severity tools, such as Performance Scales 
(self-assessment of disease status in MS; Marrie & Goldman, 2007), may shed more light onto 
functional limitations that people with MS acquire and whether the extent of these limitations 
is associated with different level of emotion dysregulation.  
 
Given that mood difficulties are prevalent in MS, it would be interesting to explore whether 
individuals with MS who have clinical levels of depression and anxiety experience greater 
emotion dysregulation, compared to those individuals with MS who do not report significant 
difficulties with mood. This study did not employed a screening instrument of depression or 
anxiety. However, participants were asked to report any psychiatric or mood disorders they 
were diagnosed with. Those who did were excluded from the study. In the context of potential 
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neurological contributors to emotion dysregulation, it has been shown that long-term myelin, 
axonal and synaptic degeneration, together with other tissue loss (such as grey matter), 
contribute to brain atrophy in MS (de Stefano, Battaglini & Smith, 2007). Since the lesion 
profile in MS is largely diffused, affecting multiple areas of both, brain and spinal cord 
functioning (Kantarci & Weinshenker, 2005), it might be more beneficial to look at brain 
volume loss, rather than lesion distribution when exploring emotion dysregulation in MS. 
Alternatively, it might prove advantageous in future studies to explore the links between 
specific neural changes resulting from MS and emotion regulation processes using imaging 
techniques. Given that MS may lead to disconnection in the frontal-subcortical brain tracts 
which are implicated in affective information processing (Adolphs, Damasio, Tranel, Cooper, 
& Damasio, 2000),it might be worthwhile to investigate whether emotion regulation abilities 
are more adversely affected in those with MS who sustained frontotemporal matter atrophy, 
than those without such changes. 
 
Lastly, self-report questionnaire measures, such as DERS require individuals to consider their 
inner emotional processes and how these affect their outer display of emotional content and 
subsequent behaviour which might be problematic for people to report adequately. Moreover, 
although a lack of insight is not consistently reported in MS (Benedict et al., 2001; Smith & 
Arnett, 2010), it is possible that individuals’ ratings reflected, to some extent, their desire to be 
perceived as having a greater control over their emotional experiences than it is actually the 
case. Social desirability and self-presentation bias play a role in self-report research, as 
adequate emotional abilities are socially highly valued, with the face validity of such tools 
being also high. For this reason, future studies might like to consider using informant-report 
measures alongside self-report measures to further increase understanding of emotion 










This work was funded by NHS Education Scotland and supported by NHS Grampian and the 





















Aldao, A., Nolen-Hoeksema, S., & Schweizer, S. (2010). Emotion-regulation strategies across 
psychopathology: A meta-analytic review. Clinical Psychology Review, 30; 217-237. 
http://dx.doi.org/10.1016/j.cpr.2009.11.004 
 
Alshubaili, A. F., Awadalla, A. W., Ohaeri, J. U., & Mabrouk, A. A. (2007). Relationship of    
depression, disability, and family caregiver attitudes to the quality of life of Kuwaiti persons with 
multiple sclerosis: a controlled study. BMC neurology, 7(1), 31. http://dx.doi.org/10.1186/1471-2377-
7-31 
Banati, M., Sandor, J., Mike, J., Illes, E., Bors, L., Feldmann, A., … Illes, Z. (2010). Social 
cognition and theory of mind in patients with relapsing-remitting multiple sclerosis. European Journal 
of Neurology, 17(3), 426–433. http://dx.doi.org/10.1111/j.1468-1331.2009.02836.x 
 
Bassi, M., Falautano, M., Cilia, S., Goretti, B., Grobberio, M., Pattini, M., ... & Lugaresi, A. 
(2016). Illness perception and well-being among persons with multiple sclerosis and their 
caregivers. Journal of clinical psychology in medical settings, 23(1), 33-52. 
http://dx.doi.org/10.1007/s10880-015-9425-8 
Benedict, R. H. B., Priore, R. L., Miller, C., Munschauer, F., & Jacobs, L. (2001). Personality 
disorder in multiple sclerosis correlates with cognitive impairment. The Journal of Neuropsychiatry and 
Clinical Neurosciences, 13(1), 70-76. http://dx.doi.org/10.1176/appi.neuropsych.13.1.70 
 
Boeschoten, R. E., Braamse, A. M., Beekman, A. T., Cuijpers, P., van Oppen, P., Dekker, J., 
& Uitdehaag, B. M. (2016). Prevalence of depression and anxiety in Multiple Sclerosis: A systematic 




Brownell, B., &Hughes, J. T. (1962). The distribution of plaques in the cerebrum in multiple 
sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 25, 315–320. 
Clark-Carter, D. (1997). Doing quantitative psychological research. From design to report. 
Psychology Press: Guildford 
Compston, A., & Coles, A. (2008). Multiple Sclerosis. The Lancet, 372(9648), 1502-1517. 
http://dx.doi.org/10.1016/S0140-6736(08)61620-7 
De Stefano, N., Battaglini, M., & Smith, S. M. (2007). Measuring brain atrophy in multiple 
sclerosis. Journal of Neuroimaging, 17(s1), 10S-15S. http://dx.doi.org/10.1111/j.1552-
6569.2007.00130.x 
Field, A. (2013). Discovering statistics using SPSS (4th ed.). London: Sage 
Fox, H. C., Axelrod, S. R., Paliwal, P., Sleeper, J., & Sinha, R. (2007). Difficulties in emotion 
regulation and impulse control during cocaine abstinence. Drug and alcohol dependence, 89(2), 298-
301. http://dx.doi.org/10.1016/j.drugalcdep.2006.12.026 
Fowler, C. & Baas, L. S. (2006). Illness representations in patients with chronic kidney disease on 
maintenance hemodialysis. Neurolog Nursing Journal, 33, 173-186.  
Garnefski, N., Koopman, H., Kraaij, V., & ten Cate, R. (2009). Brief report: Cognitive emotion 
regulation strategies and psychological adjustment in adolescents with a chronic disease. Journal of 
adolescence, 32(2), 449-454. http://dx.doi.org/10.1016/j.adolescence.2008.01.003 
Gillanders, S., Wild, M., Deighan, C., & Gillanders, D. (2008). Emotion regulation, affect, 
psychosocial functioning, and well-being in hemodialysis patients. American Journal of Kidney 
Disease, 51, 651-652. http://dx.doi.org/10.1053/j.ajkd.2007.12.023 
Gleichgerrcht, E., Tomashitis, B., & Sinay, V. (2015). The relationship between alexithymia, 




Gratz, K. L., & Roemer, L. (2004). Multidimensional assessment of emotion regulation and 
dysregulation: Development, factor structure, and initial validation of the difficulties in emotion 
regulation scale. Journal of Psychopathology and Behavioral Assessment, 26(1), 41-54. 
http://dx.doi.org/10.1007/s10862-008-9102-4.  
Gratz, K. L., & Tull, M. T. (2010). Emotion regulation as a mechanism of change in acceptance-
and mindfulness-based treatments. In R. A. Baer (Ed.), Assessing mindfulness and acceptance: 
Illuminating the processes of change. Oakland, CA: New Harbinger Publications. 
Gregg, J. A., Callaghan, G. M., Hayes, S. C., & Glenn-Lawson, J. L. (2007). Improving diabetes 
self-management through acceptance, mindfulness, and values: a randomized controlled trial. Journal 
of consulting and clinical psychology, 75(2), 336. http://dx.doi.org/10.1037/0022-006X.75.2.336 
Gross, J. J., & John, O. P. (2003). Individual differences in two emotion regulation processes: 
implications for affect, relationships, and well-being. Journal of personality and social psychology, 
85(2), 348. http://dx.doi.org/10.1037/0022-3514.85.2.348 
Gross, J. J., Sheppes, G., & Urry, H. L. (2011). Emotion generation and emotion regulation: A 
distinction we should make (carefully). Cognition and emotion, 25(5), 765-781. 
Gross, J.J., & Thomson, R.A. (2007). Emotion regulation: Conceptual foundations. In J.J.Gross 
(Ed.) (2007). Handbook of emotion regulation. The Guilford Press. New York. 
Gulick, E. E., Namey, M., & Halper, J. (2011). Monitoring my Multiple Sclerosis: A patient-
administered health-assessment scale. International Journal of MS Care, 13(3), 137–145. 
http://dx.doi.org/10.7224/1537-2073-13.3.137 
Hagger, M. & Orbell, S. (2003). A Meta-Analytic Review of the Common-Sense Model of Illness 
Representations. Psychology & Health, 18, 141-184. http://dx.doi.org/10.1080/088704403100081321 
 
Harper, A. & Power, M. (1998). Development of the World Health Organization 




Harris, R. (2009). ACT made simple: An easy-to-read primer on acceptance and commitment 
therapy. New Harbinger Publications. 
 
Hayes, A. F. (2013). Introduction to mediation, moderation, and conditional process analysis: 
A regression-based approach. Guilford Press. 
 
He, Y. (2010). Missing data analysis using multiple imputation getting to the heart of the matter. 
Circulation: Cardiovascular Quality and Outcomes, 3(1), 98-105. 
 
Henriksson, F., Fredrikson, S., Masterman, T., & Jönsson, B. (2001). Costs, quality of life and 
disease severity in multiple sclerosis: a cross‐sectional study in Sweden. European Journal of 
Neurology, 8(1), 27-35. http://dx.doi.org/10.1046/j.1468-1331.2001.00169 
 
Hohol, M. J., Orav, E. J., & Weiner, H. L. (1995). Disease Steps in multiple sclerosis. A simple 
approach to evaluate disease progression. Neurology, 45(2), 251-255. 
http://dx.doi.org/10.1212/WNL.45.2.251 
Hohol, M. J., Orav, E. J., & Weiner, H. L. (1999). Disease steps in multiple sclerosis: a longitudinal 
study comparing disease steps and EDSS to evaluate disease progression. Multiple Sclerosis, 5(5), 349-
354. http://dx.doi.org/10.1177/135245859900500508 
Jehna, M., Neuper, C., Petrovic, K., Wallner-Blazek, M., Schmidt, R., Fuchs, S., ... & Enzinger, 
C. (2010). An exploratory study on emotion recognition in patients with a clinically isolated syndrome 
and multiple sclerosis. Clinical neurology and neurosurgery, 112(6), 482-484. 
http://dx.doi.org/10.1016/j.clineuro.2010.03.020 
Jopson, N. M., & Moss-Morris, R. (2003). The role of illness severity and illness representations 




Kalmar, J. H., Gaudino, E. A., Moore, N. B., Halper, J., & DeLuca, J. (2008). The relationship 
between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychology, 
22(4), 442-449. http://dx.doi.org/10.1037/0894-4105.22.4.442 
Kantarci, O. H., & Weinshenker, B. G. (2005). Natural history of multiple sclerosis. Neurologic 
clinics, 23(1), 17-38. 
Kimhy, D., Vakhrusheva, J., Jobson-Ahmed, L., Tarrier, N., Malaspina, D., & Gross, J. J. (2012). 
Emotion awareness and regulation in individuals with schizophrenia: Implications for social 
functioning. Psychiatry research, 200(2), 193-201. http://dx.doi.org/10.1016/j.psychres.2012.05.029 
Kurtzke, J. (1983). Rating neurological impairment in multiple sclerosis: An expanded disability 
status scale (EDSS). Neurology, 33(11), 1444–1452. http://dx.doi.org/10.1212/WNL.33.11.1444 
Leventhal, H., Diefenbach, M. & Leventhal, E. A. (1992). Illness cognition: Using common sense 
to understand treatment adherence and affect cognition interactions. Cognitive Therapy and Research, 
16, 143-163. http://dx.doi.org/10.1007/BF01173486 
Leventhal, H., Nerenz, D. R. & Steele, D. J. (1984). Illness representations and coping with health 
threats. In A. Baum & J. Singer (Eds.), A Handbook of Psychology and Health (pp. 219−252). Hillsdale 
(NJ): Erlbaum 
Liverant, G. I., Kamholz, B. W., Sloan, D. M., & Brown, T. A. (2011). Rumination in clinical 
depression: a type of emotional suppression?. Cognitive Therapy and Research, 35(3), 253-265. 
http://dx.doi.org/10.1007/s10608-010-9304-4 
Lucchinetti, C. F., & Parisi, J. E. (2006). Pathology: What may it tell us? In S. D. Cook (Ed.) Handbook 
of Multiple Sclerosis (pp.113-143). New York: Taylor and Francis.  
 
Lundgren, T., Dahl, J., Yardi, N., & Melin, L. (2008). Acceptance and commitment therapy and 




Ma, Z., & Zeng, W. (2014). A Multiple Mediator Model: Power Analysis Based on Monte Carlo 
Simulation. American Journal of Applied Psychology, 3(3), 72-79. 
http://dx.doi.org/10.11648/j.ajap.20140303.15 
Marrie, R. A., & Goldman, M. (2007).Validity of performance scales for disability assessment in 
multiple sclerosis. Multiple Sclerosis,13, 1176-1182. http://dx.doi.org/10.1177/1352458507078388 
McCabe, M. P., McKern, S., & McDonald, E. (2004). Coping and psychological adjustment among 
people with multiple sclerosis. Journal of psychosomatic research, 56(3), 355-361. 
http://dx.doi.org/10.1016/S0022-3999(03)00132-6 
McCracken, L. M., & Eccleston, C. (2003). Coping or acceptance: what to do about chronic 
pain?. Pain, 105(1), 197-204. https://doi.org/10.1016/S0304-3959(03)00202-1 
McDonald, W. I., Compston, A., Edan, G., Goodkin, D. E., Hartung, H. P., Lublin, F. D., … , & 
Wolinsky, J. S. (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the 
International Panel on the diagnosis of multiple sclerosis. Annals of Neurology, 50(1), 121–127. 
http://dx.doi.org/10.1002/ana.1032 
Mikolajczak, M. & Luminet O. (2006). Is alexithymia affected by situational stress or is it a stable 
trait related to emotion regulation. Personality and Individual differences, 40, 1399-1408. 
http://dx.doi.org/10.1016/j.paid.2005.10.020 
Moss-Morris, R., Weinman, J., Petrie, K., Horne, R., Cameron, L., & Buick, D. (2002). The revised 
illness perception questionnaire (IPQ-R). Psychology and health, 17(1), 1-16. 
http://dx.doi.org/10.1080/08870440290001494 
Murphy, H., Dickens, C., Creed, F., & Bernstein, R. (1999). Depression, illness perception and 
coping in rheumatoid arthritis. Journal of psychosomatic research, 46(2), 155-164. 
http://dx.doi.org/10.1016/S0022-3999(98)00073-7 
National Institute for Clinical Excellence. (2014). Multiple Sclerosis: Management of multiple 
sclerosis in primary and secondary care. Clinical Guideline 186. London: NICE.  
122 
 
Neild, C. (2006). What is MS? Multiple Sclerosis Society. London.  
O’Connor, P. (ed.) (2002). Key issues in the diagnosis and treatment of multiple sclerosis: an 
overview. Neurology, 59, s3, s1-s31.   
Ochsner, K. N., &Gross, J. J. (2005). The cognitive control of emotion. Trends in Cognitive 
Sciences, 9, 242–249. http://dx.doi.org/10.1016/j.tics.2005.03.010 
Pakenham, K. I., & Fleming, M. (2011). Relations between acceptance of multiple sclerosis and 
positive and negative adjustments. Psychology & health, 26(10), 1292-1309. 
http://dx.doi.org/10.1080/08870446.2010.517838 
Pandey, R., Saxena, P. & Dubey, A. (2008). Emotion regulation difficulties in alexithymia and 
mental health. Europe’s Journal of Psychology, 7, 604-623. 
Petrie, K., & Weinman, J. (2006). Why illness perceptions matter. Clinical Medicine, 6(6), 536-
539. 
Phillips, L. H., Henry, J. D., Nouzova, E., Cooper, C., Radlak, B., & Summers, F. (2014). 
Difficulties with emotion regulation in multiple sclerosis: Links to executive function, mood and quality 
of life. Journal of Clinical and Experimental Neuropsychology, 36(8), 831-842. 
http://dx.doi.org/10.1080/13803395.2014.946891 
Phillips, L. H., Saldias, A., McCarrey, A., Henry, J. D., Scott, C., Summers, F., & Whyte, M. 
(2009). Attentional lapses, emotional regulation and quality of life in multiple sclerosis. British Journal 
of Clinical Psychology, 48(1), 101-106. http://dx.doi.org/10.1348/014466508X379566 
Prochnow, D., Donell, J., Schäfer, R., Jörgens, S., Hartung, H. P., Franz, M., & Seitz, R. J. (2011). 
Alexithymia and impaired facial affect recognition in multiple sclerosis. Journal of Neurology, 258, 
1683–1688. http://dx.doi.org/10.1007/s00415-011-6002-4 




Schiaffino, K. M., Shawaryn, M. A., & Blum, D. (1998). Examining the impact of illness 
representations on psychological adjustment to chronic illnesses. Health Psychology, 17(3), 262. 
http://dx.doi.org/10.1037/0278-6133.17.3.262 
Schirda, B., Nicholas, J. A., & Prakash, R. S. (2015). Examining trait mindfulness, emotion 
dysregulation, and quality of life in multiple sclerosis. Health Psychology, 34(11), 1107. 
http://dx.doi.org/10.1037/hea0000215 
Scottish Government (2011). The Matrix – a guide to delivering psychological therapies in 
Scotland. National Education for Scotland 
Skevington, S. M. (1999). Measure quality of life in Britain: Introducing the WHOQOL-100. 
Journal of Psychosomatic Research, 47(5), 5449-5459. http://dx.doi.org/10.1016/S0022-
3999(99)00051-3 
Smith, M. M., & Arnett, P. A. (2010). Awareness of executive functioning deficits in multiple 
sclerosis: Self versus informant ratings of impairment. Journal of Clinical and Experimental 
Neuropsychology, 32(7), 780–787. http://dx.doi.org/10.1080/13803390903540307 
Spain, L. A., Tubridy, N., Kilpatrick, T. J., Adams, S. J., & Holmes, A. C. N. (2007). Illness 
perception and health-related quality of life in multiple sclerosis. Acta Neurologica Scandinavica, 116, 
293-299. http://dx.doi.org/10.1111/j.1600-0404.2007.00895 
Stuss, D. T., & Alexander, M. P. (2007). Is there a dysexecutive syndrome? Philosophical 
Transactions of the Royal Society B, 362, 901–915. http://dx.doi.org/10.1098/rstb.2007.2096 
Swart, M., Kortekaas, R., & Aleman, A. (2009). Dealing with Feelings: Characterization of Trait 
Alexithymia on Emotion Regulation Strategies and Cognitive- Emotional Processing. PLoS ONE 4, 
e5751 
Tull, M. T., Barrett, H. M., McMillan, E. S., & Roemer, L. (2007). A preliminary investigation of 
the relationship between emotion regulation difficulties and posttraumatic stress symptoms. Behavior 
Therapy, 38(3), 303-313. http://dx.doi.org/10.1016/j.beth.2006.10.001 
124 
 
Van der Meer, L., van't Wout, M., & Aleman, A. (2009). Emotion regulation strategies in patients 
with schizophrenia. Psychiatry research, 170(2), 108-113. 
http://dx.doi.org/10.1016/j.psychres.2009.07.010 
van Middendorp, H., Geenen, R., Sorbi, M. J., Hox, J. J., Vingerhoets, A. J., van Doornen, L. J., 
& Bijlsma, J. W. (2005). Styles of emotion regulation and their associations with perceived health in 
patients with rheumatoid arthritis. Annals of Behavioral Medicine, 30(1), 44-53. 
Vaughn, R., Morrison, L. & Miller, E. (2003). The illness representations of multiple sclerosis and 
their relation to outcome. British Journal of Health Psychology, 8, 287- 301. 
http://dx.doi.org/10.1348/135910703322370860 
van Kessel, K., Moss-Morris, R., Willoughby, E., Chalder, T., Johnson, M. H., & Robinson, E. 
(2008). A randomized controlled trial of cognitive behavior therapy for multiple sclerosis 
fatigue.Psychosomatic Medicine, 70(2), 205-213. http://dx.doi.org/10.1097/PSY.0b013e3181643065 
Weinman, J., Petrie, K. J., Moss-Morris, R. & Horne, R. (1996). The illness perception 
questionnaire: A new method for assessing the cognitive representations of illness. Psychology and 
Health, 11, 431-445.  http://dx.doi.org/10.1080/08870449608400270 
Wynia, K., Middel, B., Van Dijk, J. P., De Keyser, J. H., & Reijneveld, S.A. (2008). The impact 
of disabilities on quality of life in people with multiple sclerosis. Multiple Sclerosis, 14, 972-980. 
http://dx.doi.org/10.1177/1352458508091260 















APPENDIX F: Supplementary Data 
 
Group Differences on Background Measures of Illness Representations and Quality of Life 
 
An Independent- Samples t-test was conducted to investigate group differences in Illness 
Identity. No significant differences were found between participants with CPMS and RRMS, 
t(114) = - 0.704, p = .483, r = .06, 95% CI [-1.58, .75]  which implies that Illness Identity is 
similar in both MS groups.  
 
For the assessment of the remaining IPQ-R subscales, a 2 x 4 mixed-design ANOVA with four 
levels of illness representations (Consequences, Personal Control, Treatment Control, or 
Emotional Representations) as the within-subject variable, and group type (RRMS vs. CPMS) 
as the between-subject variable, was conducted. This analysis revealed a significant main effect 
of group, F(1, 115) = 7.96, p =.006, ηp
2 = .065, indicating that the CPMS group rated their 
illness perceptions, on the whole, as significantly more negative than the RRMS group. There 
was also a significant main effect of IPQ-R domain F(3, 345) = 25.8, p <.001, ηp
2 = .183, but 




For the assessment of quality of life, a 3 x 4 mixed-design ANOVA with four levels of QoL 
domains (Physical, Psychological, Social, or Environmental) as the within-subject variable, 
and group type (RRMS vs. CPMS vs. HC) as the between-subject variable, was conducted. 
This analysis revealed a significant main effect of group, F(2, 169) = 9.63, p <.001, ηp
2 = .103. 
Post-hoc analyses using the Bonferroni method indicated that the CPMS group rated their 
quality of life, on the whole, significantly lower than the RRMS group (p = .003, r = .25, 95%CI 
[-13.7, -2.22]), as well as the HC group (p< .001, r = .34, 95%CI [-17.1, -4.85]). The RRMS 
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group and the HC group did not differ significantly in their overall ratings (p = .464, r = .10, 
95%CI [-2.09, 8.14]). There was also a significant main effect of QoL domains F(3, 507) = 
109.2, p <.001, ηp
2 = .393, but there was not a significant interaction between group type x 
QoL domains, F(6, 507) = 1.77, p =.102, ηp
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APPENDIX G: Initial Study Proposal 
 






Multiple sclerosis (MS) is a chronic inflammatory neurological disease of the central nervous 
system (CNS) which is the leading cause of neurological disability amongst younger adults 
(Compston & Coles, 2008). Most people are first diagnosed with a relapsing-remitting form 
of MS (RRMS; O’Connor, 2002), which involves attacks (relapses) followed by periods of 
recovery (remission). Relapses occur when inflammatory cells attack the myelin of specific 
nerves. Remission occurs when inflammation subsides and symptoms reduce. Although 
symptoms may disappear completely during remission process, after several relapses there 
may be residual damage to the myelin, resulting in partial recovery only (Neild, 2006). Most 
people initially diagnosed with RRMS later develop secondary progressive MS (SPMS; 
O’Connor, 2002), characterised by a steady increase in disability, as symptoms do not 
disappear completely after a relapse. In the primary progressive MS (PPMS), unlike in the 
RRMS, the first (primary) symptoms are progressive. They get worse over time rather than 
appearing as sudden attacks (relapses). Symptoms may continue to worsen over time or may 
become stable. The hallmark of the chronic progressive forms of MS (CPMS), namely the 
SPMS and the PPMS is the permanent loss of neural tissue (Neild, 2006). 
 
The disease tends to affect not only physical health of MS sufferers but also cognitive and 
emotional functioning. While physical and cognitive impairments present in MS, such as 
restricted mobility, reduced executive control and slowed processing speed, have been 
extensively researched (Kalmar, Gaudino, Moore, Halper, & Deluca, 2008; Rao, 1995), less 
is understood about the nature of emotional difficulties present in MS. Multiple areas of 
axonal demyelination are implicated in MS with many of the lesions arising in the white 
matter of the frontal brain regions (Brownell & Hughes, 1962). Frontal brain circuits have 
been identified in the self-regulatory process essential to executive functioning (Stuss & 
Alexander, 2007). Such circuits may also be implicated in emotion regulation processes 
(Ochsner & Gross, 2005). Since many MS sufferers display cognitive regulation difficulties 
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on executive function measures, it is plausible that emotion regulation capacity is similarly 
affected (e.g., Kalmar et al., 2008).  
 
An ability to regulate emotions involves understanding, monitoring and evaluating one’s 
affective states, as well as implementing a set of strategies to influence the subjective 
experience of emotional states, or to gain control over the outward expression of affect 
(Gross, Sheppes, & Urry, 2011). Various emotion regulation strategies can be exercised by 
individuals to manage their emotional responses and produce the desirable emotional reaction 
they wish to attain. The importance of adequate emotion regulation strategies has been widely 
recognised in clinical populations, where difficulties in emotion regulation are linked to the 
greater severity of depression, anxiety, schizophrenia, and post-traumatic stress disorder 
(Liverant, Kamholz, Sloan & Brown 2010, Van der Meer, Van’t Wout & Aleman, 2009; Tull, 
Barrett, McMillan, & Roemer, 2007), as well as lower life satisfaction, decreased 
effectiveness at work and poorer interpersonal relationships (Gross and Munoz, 1995). Also, 
emotion regulation has been identified as an important factor in psychological adaptation to 
chronic illness (Garnefski, Koopman, Kraaij & ten Cate, 2009). Thus, understanding the 
nature and cause of emotion regulation difficulties in chronic conditions such as MS is vital 
when designing interventions aimed at improving functional outcomes of those suffering 
from the disease. Moreover, treatment plans included in the NICE (186) clinical guidelines 
for the management of the MS in primary and secondary care focus primarily on physical and 
cognitive rehabilitation. Therefore, more research is needed into the emotion regulation 
difficulties of individuals with MS in order to extend the evidence base in this area and to 
incorporate emotion regulation interventions into psychological treatments offered to people 
with MS.    
 
In relation to MS, the incidence of emotion regulation difficulties has been reported for over a 
century, with first clinical accounts describing uncontrollable laughter, as well as a 
dissociation between the overt displays of affect and subjective mood reports in individuals 
with MS (Charcot, 1887; Surridge, 1969). Some of the symptoms of emotion regulation 
disturbances in MS involve pathological laughter and crying, unusual feelings of euphoria, 
emotional incontinence (disproportional exaggerated emotional expression), pseudobulbar 
affect (atypical expression of affect due to involvement of cortico-bulbar pathways), as well 
as emotional lability (dramatic shifts of mood; Feinstein, 2004; Finger, 1998; Rabins, 1990; 
Schiffer, 1990). Approximately, 10% of individuals with MS were found to experience 
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pathological laughing and crying at psychiatric consultation (Sá, 2008), whereas 73% were 
found to experience emotion dyscontrol, such as crying and irritability in the past month in 
the study by Feinstein and Feinstein (2001). Yet, it is impossible to determine whether these 
frequencies are in fact atypical due to the lack of a comparison healthy control group.  
 
The abovementioned studies of emotion regulation in individuals with MS have employed 
symptom report or clinical observation to investigate the nature of emotion regulation 
processes in this disease. Nevertheless, it is essential to examine specific aspects of emotional 
appraisal, experience and perceived control as assessed by standardized measures. To date, 
only two studies (Phillips et al., 2009; 2014) to best of our knowledge, have used 
standardised assessments to explore emotion regulation processes in MS. Phillips et al. 
(2009) measured emotion regulation strategies using the Emotion Regulation Questionnaire 
(ERQ, Gross &John, 2003) in 86 individuals with MS. The ERQ is comprised of two 
subscales measuring appraisal of emotions and expressive suppression of emotions. 
Expressive suppression involves active inhibiting of the overt manifestation of emotions in 
response to an emotional event, whereas reappraisal modifies the subjective experience of 
emotions by changing the way one evaluates or think about such emotional event. Regular 
use of such emotion regulation strategies has been found to impact on well-being, with 
repeated suppression being linked to reduced psychological and social functioning in 
individuals with rheumatoid arthritis (van Middendorp et al., 2005). Also, similar results were 
found in non-clinical populations, with individuals who routinely employ suppression 
reporting poorer life satisfaction and more depressive symptoms, compared to individuals 
who use reappraisal (Gross &John, 2003). Despite no control group for comparison purposes 
in the study of Phillips et al. (2009), it was found that the absence of reappraisal as a method 
of emotion regulation was associated with lower self-reported quality of life. However, 
similarly to the study of Feinstein and Feinstein (2001), it is not possible to deduce whether 
these frequencies differ from those in the general population. Additionally, a broader range of 
emotion regulation strategies needs to be explored in order to enhance an understanding of 
these processes in MS. 
 
These limitations were addressed in another study by Phillips et al. (2014) who investigated a 
variety of emotion regulation strategies in 31 individuals with MS and 31 matched controls 
using the Difficulties in Emotion Regulation Scale (DERS, Gratz & Roemer, 2004). This 
well-validated measure comprises of multiple subscales designed to assess discrete emotion 
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regulation processes, including acceptance of the emotion, acknowledgement and 
comprehension of the experienced emotional state, an ability to manage impulsive conduct in 
the context of negative affect, as well as an ability to employ flexible strategies to modify 
experienced emotions as required by the situational demands. It was found that individuals 
with MS reported more problems with emotion regulation than did control individuals, with a 
medium effect size (d = .68). A lack of interaction between the groups and DERS separate 
subscales, implies that different aspects of emotion regulation were similarly affected by MS.  
 
One of the main limitations of the previous studies on MS is the use of heterogeneous cohort 
of individuals with MS. It is important to differentiate between those two heterogeneous 
types of the disease, since RRMS is mainly inflammatory in nature, with symptoms of the 
disease exacerbating and diminishing, leading to partial or complete recovery, while the 
CPMS forms being characteristic of permanent nerve damage, loss (Neild, 2006) and 
subsequent worsening of symptoms. It is therefore possible that the severity of the emotion 
regulation difficulties in MS is affected by the form of the disease. If individuals with 
different variants of MS had different patterns of emotion regulation difficulties, this could 
have potential implications for symptom management and rehabilitation goals.  
 
Furthermore, none of the previous studies on emotion regulation in MS explored any 
psychosocial factors that can potentially impact on difficulties in emotion regulation and be 
possible targets of psychological intervention. One such a factor may be individuals’ illness 
representations. In the area of adjustment to chronic illness, many studies, including those on 
MS, have utilised the illness representation model to show that the perceptions that 
individuals hold about their illness are a significant predictor of adjustment, levels of social 
dysfunction, self-esteem, fatigue, as well as various mood problems (Heijmans, 1998; Jopson 
& Moss- Morris, 2003; Murphy, Dickens, Creed, & Bernstein, 1999). The illness 
representation model proposes that individuals who are diagnosed with a health condition, 
develop an organised set of beliefs about their illness. These beliefs or cognitions are defined 
as illness representations and include knowledge, experience, emotions, as well as illness-
related perceptions (Skelton & Croyle, 1991). Illness representations directly impact on 
people’s emotional response to the disease they incurred and the coping strategies they 
develop in order to reduce the negative symptoms of their illness (Petrie & Weinman, 2006). 
At the same time, such representations affect strategies that people adopt to reduce the 




Since MS is incurable, unpredictable and with substantial individual variation, it seems 
reasonable to assume that individuals with MS will develop beliefs about their illness that 
will either be helpful or detrimental to regulating their emotional responses to symptoms and 
their everyday difficulties. Schiaffino, Shawaryn and Blum (1998) investigated the 
relationship between illness representations and mood in a study of individuals with MS. 
Beliefs associated with symptom variability were linked to higher incidence of depressive 
symptoms four months down the line; this was over and above initial levels of depressed 
mood. Thus, there is some evidence that illness representations may contribute to difficulties 
with emotion regulation in individuals who develop a chronic unpredictable illness, such as 
MS. However, no studies to date have explored the impact of illness representations on 
emotion regulation in MS more directly.  
 
To address the abovementioned gaps in the literature, the current study aimed to look at the 
use of even broader range of emotion regulation strategies than in the previous studies by 
employing both of the emotion regulation measures discussed above (the ERQ and DERS) on 
the same sample of individuals with MS. More importantly, this study extends the previous 
findings by exploring the effects of different types of MS on emotion regulation abilities, 
namely relapsing-remitting MS (RRMS) and the chronic progressive forms of MS (CPMS), 
as well as healthy controls. The further objective is to investigate whether illness 
representations developed by individuals with MS impact on how they regulate their 
emotions, even when controlling for the severity of their condition. Few previous illness 
representation studies discussed above, have attempted to account for disease severity, 
making it problematic to conclude whether the relationship between emotion regulation and 
illness cognitions results in fact, from the severity of the condition itself..  
 
Research Questions / Objectives: 
 
2) What is the principal research question / objective?  
 
To explore whether individuals presenting with different variants of MS, namely RRMS and 





3) What are the secondary research questions / objectives if applicable?  
 
To explore whether negative illness representations predict emotion dysregulation in MS, 
independently of disease severity.  
 
More specifically, it was hypothesized that individuals who have a strong illness identity, a 
poor sense of control over their illness and believe their disease to have had detrimental 
consequences on their lives, will have more difficulties with emotion regulation, after 




4) Please give a full summary of your design and methodology. It should be clear exactly 
what will happen at each stage of the project. (Relevant to IRAS A13).  
 
Some of the data has been previously collected by the candidate during her doctoral studies at 
the University of Aberdeen. However, it has not been included in the actual PhD thesis. As 
such, ethics applications were reviewed and approved by the NHS NRES Committee North 
East - Sunderland (Research Ethics Committee (REC) Reference 12/NE/0130; fully approved 
on 23rd March 2012). Major amendment or new ethical application will be submitted to the 
REC in order to be able to further recruit participants with MS and Healthy Controls.   
 
General aspects of the research design:   
The basic principle of the study method is to use standardised self-report questionnaires that 
participants will fill in in the comfort of their own home. It will take 30-50 minutes for the 
questionnaires to be filled in. No risk is associated with the measures used. All questionnaires 
were well standardised and validated and have been used in previous studies with other clinical 
populations, including MS. 
 
Participants: 
In total, 270 individuals with MS listed on the Department of Neurology (NHS Grampian) MS 
database were contacted by means of an Invitation Letter, Participant Information Sheet, and 
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Reply Form, with stamped addressed envelopes being sent to their home address. Out of these, 
42 invitations were declined, 9 were undelivered, 145 were not returned, and 74 consented to 
participate (43% response rate: composed of invitations consented and declined) Out of the 
initial 74 potential participants, seven were unable to take part as they experienced a relapse, 
and nine further declined due to unforeseen circumstances. The remaining 58 MS participants 
were assessed in this study. Another two participants were excluded on the basis of co-
morbidity. Thus, data from 56 individuals with MS were included in the analysis. 31 HC 
participants were recruited from the general community via word of mouth, friends/relatives 
of MS participants, and the Aberdeen University Participation Panel. 
 
Further recruitment of participants with MS: 
Potential participants with MS will be identified by the MS Nurse using the Department of 
Neurology’s MS Patient Database at Aberdeen Royal Infirmary. An Invitation Letter outlining 
the purpose of the research will be sent to potential participants by the Consultant Clinical 
Neuropsychologist. An enclosed Information Sheet will provide details about participation. A 
Reply Form requesting volunteers’ contact details will be attached to this letter, together with 
a Consent Form. A stamped, addressed envelope will be provided to enable participants to 
return their Reply and Consent Forms. The researcher will telephone those individuals who 
express an interest in the study to discuss any questions they might have about the research and 
to clarify whether they are still willing to participate. After receiving a signed Consent Form, 
the participant will then be sent a set of questionnaires (with an allocated study number) to fill 
in and return in the envelope provided.  
 
Further recruitment of participants without MS: 
HC participants matched for age, gender and education will be further recruited though 
collaboration with the University of Aberdeen Research Participant Panel and friends/relatives 
of the MS participants. HC participants will be initially contacted by phone. Once they agree 
to participate, an enclosed Information Sheet, Consent Form, as well as stamped, addressed 
envelope will be sent. The researcher will telephone those individuals who return their signed 
Consent Forms to discuss any remaining questions they might have about the research. Each 
participant will then be sent a set of questionnaires (with an allocated study number) to fill in 





These are discussed in section 6 
 
5)  Please list the principal inclusion and exclusion criteria  
 
For MS participants, the following inclusion criteria were applied: 
1. Must meet McDonald Criteria for MS diagnosis (Relapsing-remitting or progressive types, 
as defined by a Consultant Neurologist – to ensure that participants met clinically accepted 
MS diagnostic criteria. 
2. Aged 18+ - to avoid confounding effects of developmental changes in emotional skills and 
cognitive function. 
Participants were excluded if they met any of the following criteria:  
1. Deemed not to have capacity to consent- to avoid problematic issues of consent in this 
population. 
2. A pre-morbid history of neurological disease (other than MS), traumatic brain injury, 
psychiatric disorder, severe alcohol or drug abuse - to avoid these as confounding factors. 
3. Poor understanding of English that would negatively affect their ability to complete 
behavioural tasks, questionnaires or understand test instructions. 
4. Current optic neuritis, or other severe visual or hearing impairment, and severe motor 
disturbances that would negatively affect their ability to satisfactorily complete measures or 
understand test instructions. 
 
For Healthy Control participants, the following inclusion criteria were applied: 
 
1. Aged 18+ - to avoid confounding effects of developmental changes in emotional skills and 
cognitive function. 
 




1. A pre-morbid history of neurological disease, traumatic brain injury, psychiatric disorder, 
severe alcohol or drug abuse - to avoid these as confounding factors. 
2. Poor understanding of English that would negatively affect their ability to complete 
behavioural tasks, questionnaires or understand test instructions. 
3. Severe visual or hearing impairment and severe motor disturbances that would negatively 
affect their ability to satisfactorily complete measures or understand test instructions. 
 
6) How will data be collected? 
 
The following self-report measures were chosen as they were shown to have good 
psychometric properties and have been commonly used to measure emotion regulation, illness 
representations and disease severity, respectively, in MS.  
 
1) The Difficulty in Emotion Regulation Scale (DERS; Gratz, & Roemer, 2004) is a 36-item, 
self-report measure designed to assess multiple aspects of emotion dysregulation. The 
DERS was chosen to reflect difficulties in 6 domains of emotion regulation: 1) acceptance 
of emotion (nonacceptance), 2) the ability to refrain from impulsiveness when experiencing 
negative moods (impulse), 3) the ability to direct behaviour towards goals and targets despite 
experiencing negative emotions (goals), 4) awareness of emotions (awareness), 5) 
understanding and clarity about emotions experienced (clarity) and 6) the ability to access 
emotion regulation strategies (strategies). Participants are required to read a series of 
statements regarding their emotions and feelings and they must circle the response that most 
accurately describes them. Higher scores are indicative of greater difficulties in emotion 
regulation. The DERS was found to have high internal consistency, α = .93 (Gratz & 
Roemer, 2004), with the six scales forming replicable factors that show adequate evidence 
of external validity (Weinberg & Klonsky, 2009), as well as a prediction of behavioral 
assessments of emotion regulation (Vasilev, Crowell, Beauchaine, Mead, & Gatzke-Kopp, 
2009).  
 
2) The Emotion Regulation Questionnaire (ERQ; Gross & John, 2003) measures the habitual 
use of two most frequently applied emotion regulation strategies, namely cognitive 
reappraisal (e.g. ‘When I want to feel more positive emotion, I change what I’m thinking 
about’) and expressive suppression (e.g. ‘I keep my emotions to myself’). Six questions aim 
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to assess cognitive reappraisal which involves changing one’s perspective on the situation. 
The remaining four questions assess expressive suppression which involves executing some 
control over one’s emotions by not openly expressing them. It is a 10-item scale. Participants 
are asked to indicate the extent to which they agree with each statement. Higher scores 
indicate more frequent use of each strategy. This questionnaire has been found to display 
adequate psychometric properties of validity and reliability (Gratz & Roemer, 2004; Ehring 
et al., 2008).  
 
3) The Illness Perceptions Questionnaire-Revised (IPQ-R; Moss-Morris et al., 2002) is one of 
the most widely used instruments that measure patient’s illness perceptions. It is composed 
of two sections; the first section includes eight subscales that assess cognitive 
representations of the illness, while the second section evaluates emotional responses to the 
disease on a single subscale. Different dimensions of cognitive representations include 
cause, timeline, identity, consequences, and control. The control aspect of the IPQ-R is 
subsequently divided into treatment and personal control beliefs. Personal control beliefs 
represent individual’s conviction about their own capability to exert control over their 
symptoms, whereas treatment control beliefs refer to the people’s level of certainty in their 
treatment as an effective way of controlling the condition. The timeline dimension is further 
split into an acute, chronic and cyclical subscales (i.e., whether the individual perceives their 
condition and symptoms as short- term, long-term, or recurring in nature). A new dimension 
of illness coherence assesses the degree to which individuals think they hold a coherent 
understanding of their illness. All items are rated on a five-point Likert scale, ranging from 
strongly agree to strongly disagree, with the exception of items included in the identity 
dimension. The identity dimension requires the rater to indicate on a yes/no scale whether 
they believe a set of frequently occurring symptoms to be related to their condition.  
 
For the purposes of the current study, three additional MS-specific symptoms, namely 
speech distortions, clumsiness and numbness, were included in the initial 14-item identity 
list. These items are coded in a way that high ratings reflect strong beliefs on the specific 
dimension. Hence, high ratings on the timeline, identity, and consequences subscales 
represent the chronicity of the disease, the negative convictions about some symptoms 
related to MS, as well as the negative impact of the consequences of having the conditions, 
respectively. High ratings on the coherence and control dimensions reflect how well 
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individuals feel they understand their illness, as well as more positive beliefs about how 
manageable they feel their condition is. Higher ratings on the emotional representation 
subscale represent a strongly negative emotional reaction to the condition. The IPQ-R has 
shown good criterion, construct and known-groups validity (Jopson & Moss-Morris, 2003).  
 
4) The Patient Determined Disease Steps (PDDS) questionnaire was specifically constructed 
for an assessment of MS progression and functional disability resulting from MS Hohol, 
Orav and Weiner (1995). It is based primarily on ambulation. Hohol et al., (1995) noted at 
the time that clinical scales of MS were too often complex to administer without adequate 
and costly training, were insensitive to disease progression, as well as unacceptable levels 
of inter-rater variability. Hence, they designed the PDDS which is an ordinal rating scale 
comprised of nine classifications: 0 = ‘Normal, mild symptoms or signs, mostly sensory’, 1 
= ‘Mild Disability, noticeable symptoms, still minor’, 2 =‘Moderate disability, no gait 
problems, but other disabling symptoms’, 3 = ‘Gait disability, significant gait problems’, 4 
= ‘Early cane, intermittent use of cane’, 5= ‘Late cane, cane-dependent’, 6 = ‘Bilateral 
support’, 7 = ‘Confined to wheelchair’ and 8= ‘Bedridden’. Ratings range from 0-8, and 
their aim is to categorise individuals into three groups, in accordance with their disability 
level: a score of 0-2 reflects ‘mild disability’ characterized by no walking limitation but 
some sensory symptoms; a score of 3-5 reflects ‘moderate disability’ characteristic of 
walking difficulties, and a need for a cane; a score of 6-8 is reflective of  ‘severe disability’ 
indicating a need for bilateral support, use of wheelchair or being bedridden (Gulick, 
Namey, & Harper, 2011). Hohol et al. argue that raters were able to quickly and easily 
categorise the standardisation sample of 1323 individuals with MS using the PDDS.  
 
 Inter-rater reliability for the PDDS in a sample of 60 patients was excellent (kappa = .80), 
as compared to a moderate result for the Expanded Disability Status Scale (EDSS) (kappa 
= .54) which is the most frequently employed clinical outcome measure in MS (Kurtzke, 
1983). A longitudinal study, which used the PDDS and EDSS for an assessment of MS 
progression, found similar evaluations resulting from the two measures, as well as strong 
associations with each other at baseline (Spearman r = .94, n = 789, p = .0001), and over 
time: at 1 year, r = .55, n = 658, p = .0001; at 2 year, r = .64, n = 507, p = .0001; and at 3 
year, r = .62, n = 330, p = .0001 (Hohol, Orav, & Weiner, 1999). These findings support the 
validity of the PDDS and its employment as a practical and simple tool for an evaluation of 
MS progression (Hohol et al., 1999). 
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7) What sample size is needed for the research and how did you determine this?   
 
Estimation of the sample size depends on the strength of the relationship that is being explored 
(effect size) and the amount of statistical power required to be able to detect such effects (Field, 
2013). To address our primary research questions (differences in emotion regulation abilities 
in different variants of MS, as compared to HC) would require conducting a series of one-way 
ANOVAs comparing the MS groups to the HC participants on different emotion regulation 
abilities. Therefore, a sample size was determined by carrying out a power analysis using 
G*Power 3.1, with an alpha level of 0.05, and a medium effect size (f = .25). This led to a 
predictive total sample size (two MS groups and HC) of 159 with an actual power of .80. Our 
actual total sample size was 87, with 30 participants with RRMS, 26 participants with CPMS 
and 31 HC participants. Thus, further 72 participants (MS = 50, HC = 22) will need to be 
recruited through the Department of Neurology research database at Aberdeen Royal 
Infirmary. This database currently contains details on over 600 MS patients whereas a required 
response rate for this study is 8.3%. Thus, we do not anticipate major difficulty in achieving 
appropriate recruitment rates.  
In order to address our secondary research question (whether negative illness representations 
predict emotion dysregulation in MS, independently of disease severity), hierarchical 
regression will be conducted. Therefore, a sample size was determine by carrying out a power 
analysis using again G*Power 3.1, with an alpha level of 0.05, a medium effect size (f2 = .15), 
and 4 predictors (illness identity, control, consequences and disease severity). This led to a 
predictive total sample size (two MS groups and HC) of 85 with an actual power of .80. As 
discussed above, we do not anticipate major difficulty in achieving appropriate recruitment 
rates.  
Although, to our knowledge, there are no published studies of emotion regulation to date that 
distinguished between different types of MS and HC, the typical sample sizes in behavioural 
studies of emotional skills is 20- 40 for MS participants (Banati et al., 2010; Jehna et al., 2010). 
 
 
8) Outline reasons for your confidence in being able to achieve a sample of at least this 
size. (e.g. by giving details of size of known available sample(s), percentage of this type of 





Data from 87 participants (MS = 56, HC = 31) has already been collected. Thus, further 72 
participants (MS = 50, HC = 22) will need to be recruited through the Department of Neurology 
research database at Aberdeen Royal Infirmary. This database currently contains details on 
over 600 MS patients whereas a required response rate for this study is only 8.3%. Thus, we 
do not anticipate major difficulty in achieving appropriate recruitment rates. Control 
participants, matched for age, gender and education will be further recruited though 
collaboration with the University of Aberdeen Research Participant Panel and friends/relatives 
of the MS participants. Also, the project timescale dedicates a significant timescale of 5 months 
for the recruitment. 
Analysis 
9) Please describe the methods of analysis (statistical or other appropriate methods, e.g. 
for qualitative research) by which the data will be evaluated to meet the study objectives.  
 
Initially data will be analysed using descriptive statistics and will be graphed and explored 
using the Statistical Package for Social Sciences (SPSS) to see whether the data is meeting the 
necessary assumptions for the use of parametric testing. 
 
The main research question will be analysed using one-way Analysis of Variance (ANOVA). 
 
For the secondary research question, the data will be initially inspected by graphing scatterplots 
to assess whether there is a linear relationship between the variables, important for meaningful 
interpretation of the correlation coefficient.  
 
Further, hierarchical regression analysis will be used to address the extent to which illness 
representations predict difficulties in emotion regulation in the sample of MS participants. 
Hierarchical regression will control for factors such as disease severity. 
 




10)  Please summarise the main potential risks to your study, the perceived likelihood of 
occurrence of these risks and any steps you will or have taken to reduce these risks. 
Outline how you will respond to identified risks if they should occur.  
 
1. There is a potential risk that the amendment to this study or new application will not be 
approved by the REC or will require some alterations in order to be granted an approval. 
The perceived likelihood of occurrence of this risk is rather small due to the following 
factors; the time taken to complete the study will be significantly reduced from over two 
hours to approximately 50 minutes. Participants will be able to complete the study in the 
comfort of their own home, without incurring additional time and travel costs. The 
measures that have been chosen have been selected to minimise the duration of testing. 
They are not assessing particularly sensitive or upsetting issues, yet there are a few 
questions contained within questionnaires which do deal with personal issues. However, 
as all these measures have been used with many clinical populations, including the MS 
population previously, therefore, we do not anticipate any difficulties arising with the 
chosen measures. Moreover, the questionnaires sent will be anonymised. Once participants 
consented to take part in the study (by filling in and sending back the reply form and 
consent sheet), they will be assigned individual study numbers that will be put onto all 
questionnaires and send to the participant in a separate letter to ensure confidentiality. No 
identifiable, sensitive information will be posted with the questionnaires. Feedback from 
supervisors will be sought before submission of the amendment to the REC. Lastly, a 
generous amount of time has been allocated to the ethical approval process (5 months) 
should any difficulties arise.  
 
2. There is a potential risk that the number of participants (total sample size = 159) required 
for statistical power of .8 will not be achieved. The perceived likelihood of this risk is 
again low. Data from 87 participants (MS = 56, HC = 31) has already been collected. Thus, 
further 72 participants (MS = 50, HC = 22) will need to be recruited through the 
Department of Neurology research database at Aberdeen Royal Infirmary. This database 
currently contains details on over 600 MS patients whereas a required response rate for 
this study is 8.3%. Thus, we do not anticipate major difficulty in achieving appropriate 
recruitment rates. Control participants, matched for age, gender and education will be 
further recruited though collaboration with the University of Aberdeen Research 
Participant Panel and friends/relatives of the MS participants. Also, the project timescale 






11) How do you intend to report and disseminate the results of the study?   
 
This study will be written up in a format of a doctoral thesis and submitted to the Doctorate of 
Clinical Psychology Programme at the University of Edinburgh. The thesis will be composed 
of a systematic review and a journal article which will be subsequently submitted to the 
Multiple Sclerosis Journal, a peer-reviewed international journal focused on all aspects of 
Multiple Sclerosis. The finding from this study will be presented locally within NHS Grampian 
and the Neuropsychology Department, as well as in 
the local Stuart Resource Centre for people with MS. The candidate also intends to present the 
findings at the MS Frontiers Conference in 2017.  
 
13) What are the anticipated benefits or implications for services of the project? (E.g. If 
this is an NHS based project, in what way(s) is the project intended to benefit the NHS?) 
 
This study will provide reliable and valid information on the nature of emotion regulation 
difficulties that people with different types of MS experience in their everyday life. Very little 
is known regarding emotion regulation in MS, and these difficulties do not seem to be targeted 
by current psychological interventions. Current psychological treatments focus primarily on 
cognitive rehabilitation in MS. Therefore, this research project will benefit the NHS Grampian 
Neuropsychology Department by increasing an understanding of the potential emotion 
regulation difficulties in MS and provide basis for designing an intervention that can target 
such difficulties. If illness representation underlies emotion dysregulation in MS, adjusted CBT 
treatments can be designed to help challenge unhelpful illness cognitions, which in turn, might 
help manage emotion regulation problems in this patient group.  
